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Spinocerebellar ataxia 1 (SCA1) is part of a broader group of dominant 
neurodegenerative disorders caused by an unstable CAG trinucleotide repeat. There is 
no known cure for this disease and symptoms worsen progressively culminating in 
death. The disease-causing mutation in SCA1 occurs in the ATXN1 gene. The function 
of the gene product (the ataxin-1 protein) is unknown, however; the protein has been 
linked to RNA processing in the cell.  
The first part of this study followed on a 1997 report of two founder haplotypes in the 
Mixed Ancestry SCA1 families in the Western Cape of South Africa, using 
microsatellites. The aim was to narrow the region investigated in the previous study, and 
confirm the existence of founder haplotypes using a SNP-based haplotype. The SNP-
based haplotype was constructed using 4 SNPs in individuals from 5 different families 
of Mixed Ancestry origin from the Western Cape and the two founder events were 
confirmed. The SNP-based haplotype also shows the existence of a minimum common 
interval and indicates regions of possible break-points which may be useful in 
determining the extent and origins of the two haplotypes. 
The second aim of the study was to preferentially silence the mutant transcript of the 
ATXN1 gene by targeting a single nucleotide difference. Two of the SNPs genotyped 
for the SNP-based haplotype were found to be heterozygous in over half of the patient 
cohort. Eight shRNA effector molecules were screened against short target sequences 
incorporating one of these SNPs. Results are promising, with significant discrimination 
achieved between the wild-type and mutant alleles by targeting this SNP. This study has 
shown that RNAi may be developed as a beneficial therapeutic technique for a subset of 















1.1 Polyglutamine disorders 
The polyglutamine (polyQ) diseases are a large group of inherited neurodegenerative 
disorders. They include Huntington disease (HD), dentatorubral-pallidoluysian atrophy 
(DRPLA), spinobulbar muscular atrophy (SBMA) as well as the spinocerebellar ataxias 
type 1, 2, 3, 6, 7 and 17 (Zoghbi and Orr 2000, Soong and Paulson 2007). For these nine 
known polyQ disorders, the disease-causing mutation is an unstable expansion of a 
trinucleotide (CAG) repeat in the respective gene that leads to an abnormally long 
polyglutamine tract in the protein. Transmission of these large unstable alleles results in 
further expansion in subsequent generations, a phenomenon known as „anticipation‟ 
(Margolis 2002, Soong and Paulson 2007). Apart from SBMA, the polyQ diseases are 
dominantly inherited, and longer CAG tracts usually correlate with an earlier age-of-
onset as well as more severe symptoms. 
 
The genes causing these degenerative disorders show no homology to each other 
outside of the glutamine repeat, and most encode proteins that are ubiquitously 
expressed (Zoghbi and Orr 2000). Despite widespread expression of the gene product, 
each disease is characterised by a unique pattern of selective neuronal death within the 
central nervous system (CNS) that leads to the observed clinical symptoms. The exact 
mechanism for this selectivity remains elusive. The dominant pattern of inheritance as 
well as evidence from animal models supports a model of disease in which 
polyglutamine expansion confers a toxic gain-of-function on the protein (Ross 1997, 
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The neurotoxic properties probably involve an increased propensity for the disease 
protein to misfold and aggregate, resulting in the formation of neuronal intranuclear 
inclusions (NIIs) which have been found in neurons susceptible to the disease process 
in the polyQs (Skinner et al. 1997, Perez et al. 1998, Yamada et al. 2008). 
 
1.2 Spinocerebellar ataxia 1 
Spinocerebellar ataxia 1 (SCA1) is one of a group of autosomal dominant 
neurodegenerative disorders known as the spinocerebellar ataxias (SCAs). SCA1 is 
reported to account for 6% of all dominant ataxia (La Spada and Taylor 2010). Like all 
the inherited ataxias, SCA1 is characterised by loss of motor coordination and balance. 
More specific clinical features include slurred speech, difficulty swallowing, spasticity 
and cognitive impairments (Zoghbi and Orr 2009). In 1993, Orr and colleagues 
identified the disease-causing mutation in SCA1, showing it to be an expansion of a 
trinucleotide repeat (CAG) in the ATXN1 gene which encodes the ataxin-1 protein 
(Orr et al. 1993). It was the first of the SCAs for which the causative gene was identified 
and characterised. The mutation leads to an abnormally long polyglutamine tract in the 
translated protein, the distinguishing feature of polyQ disorders. 
 
In SCA1, selective neuronal death of the cerebellar Purkinje cells, inferior olivary cells 
and other brainstem nuclei, results in the observed symptoms (Klement et al. 1998). The 
disease is progressive and as yet incurable. Symptoms typically appear between 20 and 
50 years of age and worsen progressively; resulting in death 10 to 20 years after the 
initial onset (Burright et al. 1995, Bryer et al. 2003). There are also reports of juvenile 
onset SCA1, where disease symptoms are more severe and progression is more rapid 
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Normal SCA1 alleles are highly polymorphic with 6 to 39 CAG repeats (Zühlke et al. 
2002). The alleles in the upper limit of this range (36-39) are known as mutable normal 
or intermediate alleles. An analysis of these intermediate alleles performed by Zühlke 
and colleagues suggests a change from normal to pathogenic at 39 repeats depending on 
the presence of CAT interruptions within the CAG tract (Zühlke et al. 2002). Normal 
alleles with more than 20 repeats usually have between 1 and 3 CAT interruptions which 
are believed to be important in maintaining their stability during DNA replication, 
making them unsusceptible to intergenerational expansion (Chung et al. 1993, Orr and 
Zoghbi 2001). Pure CAG tracts however are dynamic; thus normal alleles carrying a 
pure tract are likely to expand into the disease-causing range on transmission. 
Symptomatic individuals have been reported to carry expanded alleles with 39 to 81 
uninterrupted CAG repeats. An individual with juvenile-onset SCA1 was found to carry 
91 repeats (Chong et al. 1995). Due to the unstable nature of the pure CAG tract, 
expanded alleles from symptomatic individuals may result in anticipation in the next 
generation (Orr and Zoghbi 2001, Zühlke et al. 2002, Soong and Paulson 2007).  
Anticipation is a common phenomenon in SCA1 and refers to the tendency for a 
disease to worsen from one generation to the next within the same family as a result of 
larger expansions causing the earlier onset of disease symptoms (Soong and Paulson 
2007). 
 
Chong et al. reported somatic instability of the ATXN1 CAG tract especially in tissues 
with higher mitotic potential such as sperm cells and peripheral blood cells (Chong et al. 
1995). This may explain the observation of an unbalanced transmission of expanded 
alleles with larger alleles being transmitted by the male parent (Chung et al. 1993, Jodice 
et al. 1994). In contrast, maternal transmission of expanded alleles tends to be stable and 














The ATXN1 gene on the short arm of chromosome 6 consists of nine exons, spanning 
approximately 450 kilobase pairs (kb) of genomic DNA. The first seven exons cover the 
5‟ untranslated region (UTR) and the last two large exons 8 and 9, cover the coding 
region and the 3‟ UTR. The coding region is only 2448 base pairs (bp) long (Zoghbi et 
al. 1991, Banfi et al. 1994, Servadio et al. 1995). Importantly, ATXN1 undergoes 
alternative splicing in various tissues. The gene encodes ataxin-1, a 98 kiloDalton (kDa) 
soluble protein of approximately 816 amino acids (aa) depending on the number of 
CAG repeats. The protein is expressed in a variety of cells of the nervous system as well 
as in peripheral tissues; however its specific function is as yet unknown. 
Immunohistochemical studies have revealed that expression of endogenous ataxin-1 is 
cytoplasmic in non-neuronal cell types and nuclear in neuronal cells of the brain 
(Servadio et al. 1995, Burright et al. 1995). However, in the Purkinje cells of the 
cerebellum the site of SCA1 pathology, endogenous ataxin-1 has both nuclear and 
cytoplasmic localization.  
 
The protein consists of two functionally different domains: the ataxin-1/HBP1 (High-
mobility group box 1) – AXH domain near the C-terminus of the protein and the amino 
terminal region which contains the polyglutamine tract. The protein also has a C-
terminal nuclear localisation signal (NLS) that serves to target it to the nucleus (Klement 
et al. 1998). The AXH domain has been implicated in self-association (Burright et al. 
1997), RNA-binding (Yue et al. 2001) and it is known to facilitate ataxin-1‟s interaction 
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Ataxin-1‟s ability to bind to RNA as well as its interactions with numerous proteins, 
most of which are involved in transcriptional regulation and RNA metabolism, point to 
a possible role in RNA processing. The protein has been shown to interact with several 
transcriptional co-regulators including: polyQ-binding protein 1 (PQB1) (Okazawa et al. 
2002), silencing mediator of retinoid and thyroid hormone receptors (SMRT) (Tsai et al. 
2004), Gfi-1/Senseless (Tsuda et al. 2005), leucine-rich acidic nuclear protein (LANP) 
(Cvetanovic et al. 2007), specificity protein 1 (Sp-1) (Goold et al. 2007) and the ubiquitin-
conjugating enzyme UbcH6 (Lee et al. 2008).  
 
A recent study explored the very complex process of ubiquitination and the role ataxin-
1 plays within that process (Hong et al. 2008). The ubiquitin system-mediated post-
translational modification and degradation of proteins is important for regulating the 
activity of normal proteins and to avoid the toxic effect of misfolded proteins. Thus, 
ataxin-1 appears to have an important role in cellular homeostasis. 
 
1.4 SCA1 pathogenesis 
The 1990‟s have been referred to as the “decade of the brain” (Cummings et al. 1999). 
This period saw rapid progress in neurogenetics research and on the SCAs in particular.  
 
Early work attempted to elucidate the normal function of ataxin-1. Burright et al. 
established the first mouse model for SCA1 (Burright et al. 1995). The group generated 
transgenic mice expressing the human SCA1 gene using the promoter elements of the 
murine Pcp2 gene that directs expression specifically to the Purkinje cells. The 
transgenes contained either a normal interrupted allele with 30 repeats or an expanded 
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The animals with the expanded SCA1 allele developed ataxia and loss of Purkinje cells 
(Burright et al. 1995). On the other hand, the transgenic mice expressing the unexpanded 
human SCA1 allele exhibited normal Purkinje cell numbers indicating that expression of 
expanded CAG repeats was sufficient to cause degeneration and ataxia.  
 
To further investigate the function of ataxin-1, another mouse model was generated 
with a targeted deletion in the mouse Sca1 gene (Matilla et al. 1998). Mice lacking ataxin-
1 did not show evidence of ataxia or neuronal cell loss. However, Sca1 null mice did 
show neurobehavioral abnormalities associated with learning and memory. These 
findings pointed to a gain-of-function of the mutant protein and a possible role of 
ataxin-1 in learning and memory (Matilla et al. 1998). 
 
 1.4.1 Protein aggregation 
At this stage, nuclear aggregates containing the disease proteins had been discovered in 
a number of polyQ diseases including SCA1 (Skinner et al. 1997) and HD (Davies et al. 
1997). The aggregates were identified post-mortem in brain tissue from human patients 
as well as in neurons taken from transgenic mice. Aggregation was therefore suggested 
as the common mechanism of neuropathology (Ross 1997, Perez et al. 1998, Davies et al. 
1998). To examine this hypothesis in SCA1, Klement and colleagues (Klement et al. 
1998) generated two lines of transgenic mice both with an expanded form of ataxin-1, 
one containing a mutated NLS and the other a deletion in the previously identified self-
association region (Burright et al. 1997). In the first line (carrying the mutated NLS), the 
mutant form of the protein localised largely to the cytoplasm and the mice did not 
develop ataxia or degeneration (Klement et al. 1998). The second line (carrying the 
deletion) in which the mutant protein was able to localise to the nucleus showed 
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Therefore, although nuclear localisation is critical, nuclear aggregation of ataxin-1 is not 
necessary for pathogenesis. Aggregates have also been shown not to correlate with 
localisation of cellular protein in other polyQ diseases such as HD (Klement et al. 1998). 
 
Several other studies have provided further understanding of the pathogenic mechanism 
underlying the polyQ disorders using SCA1 as a basis. A study of knock-in mice with 78 
CAG repeats in the mouse Sca1 locus showed no evidence of neuropathological changes 
up to 18 months of age (Lorenzetti et al. 2000). The mice homozygous for mutant 
ataxin-1 showed impaired motor coordination and intergenerational repeat instability 
compared to their wild-type littermates. However, histological examination of brain 
tissue from mutant mice up to 18 months showed none of the changes observed in 
other models over expressing expanded polyglutamine tracts. This data suggested that 
prolonged exposure to mutant ataxin-1 is necessary to produce the SCA1 phenotype 
and pathogenesis is thus a function of both the polyglutamine expanded protein and the 
duration of neuronal exposure to mutant protein (Lorenzetti et al. 2000). This could 
explain the late onset of disease symptoms seen in the majority of SCA1 patients. 
 
The formation of NIIs (mentioned in section 1.1), although not required for 
pathogenesis was still thought to play an important role (Kaytor and Warren 1999). NIIs 
have been shown to contain ubiquitin and molecular chaperones, components of the 
cell‟s protein degradation and re-folding machinery. Cummings et al. hypothesised that 
protein misfolding and impaired clearance may lead to observed SCA1 pathology 
(Cummings et al. 1999). SCA1 transgenic mice crossed with mice over-expressing the 
molecular chaperone, inducible heat shock protein 70 (iHSP70), demonstrated that high 
levels of HSP70 protect against neurodegeneration, suggesting the upregulation of 
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Several reports have shown the benefit of this strategy in other polyQ disorders. 
Geranylgeranylacetone, an acyclic isoprenoid compound used as an oral anti-cancer 
drug was previously shown to induce expression of heat shock proteins (Hsps) in 
different tissues. Oral administration of this compound led to improved motor 
behaviour and survival of transgenic SBMA mice (Bauer and Nukina 2009). Another 
compound, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) a known Hsp90 
inhibitor, has also been reported to improve neurodegeneration in SBMA mice. In 
Drosophila models of SCA3 and HD, 17-AAG has been shown to suppress 
polyglutamine-induced neurodegeneration by activation of heat-shock factor 1 which in 
turn up-regulated molecular chaperones Hsp40, Hsp70 and Hsp90. In another study, an 
analogue of 17-AAG was used to ameliorate the phenotype in SBMA transgenic mice 
(Tokui et al. 2009). The use of molecular chaperones in SCA1 therapy thus requires 
further investigation. 
 
 1.4.2 SCA1 selectivity 
Different hypotheses have been put forward to explain the selective nature of neuronal 
cell death. One hypoth sis was that cell-specific expression levels and patterns of other 
proteins such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and leucine-rich 
acidic nuclear protein (LANP) interacting with the polyglutamine expanded ataxin-1, 
contributed to the observed selectivity (Timchenko and Caskey 1999). Another 
suggested that the ability to process and degrade toxic mutant proteins differed between 
neuronal cells, resulting in the degeneration of the more vulnerable cell types (Watase et 
al. 2002). Yet another hypothesis proposed somatic instability and further repeat 
expansion in particular cell types as a mechanism for the selectivity (Kennedy and 
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Although huntingtin protein expression levels are unchanged in HD knock-in mice, 
experiments showed unexpectedly high levels of repeat length variation in different 
tissues. The authors suggested that mechanisms of repeat instability in terminally 
differentiated tissue may differ significantly from those in the germ line and thus 
multiple rounds of DNA damage and repair could mediate mutation instability in post-
mitotic cells (Kennedy and Shelbourne 2000).  
 
An investigation by Watase and colleagues addressed the somatic and intergenerational 
repeat instability of the expanded allele in a knock-in SCA1 mouse model (Watase et al. 
2003). The group studied maternal and paternal transmission of expanded alleles and 
the size of expansions in different somatic tissues. Results showed that the degree of 
instability was much less remarkable in the cerebellum compared to that in the striatum 
of mutant animals. This and the failure to find any „hyper‟-expanded allele in the 
cerebellum suggests the absence of a direct link between somatic CAG repeat instability 
and selective neuronal vulnerability (Watase et al. 2003). The reason for neuronal 
selectivity in the polyQs has still not been defined. 
 
 1.4.3 Post-translational modifications and protein interactions 
In 2003, two groups reported the importance of post-translational modifications in the 
ataxin-1 protein. Emamian and colleagues showed that the serine at position 776 (S776) 
in both wild-type and mutant ataxin-1 was phosphorylated in transfected cells and 
transgenic mice. Changing the serine at this position to an alanine, suppressed the 
toxicity of the mutant protein. Phosphorylation was shown to be linked to the protein‟s 
transport into the nucleus and increased the protein‟s ability to form NIIs, both of 
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In another study using a Drosophila model of SCA1, Chen and colleagues reported the 
interaction of both wild-type and mutant ataxin-1 with the 14-3-3 protein, a 
multifunctional regulatory molecule (Chen et al. 2003). The authors suggest that 14-3-3 
regulates ataxin-1‟s clearance under normal physiological conditions, either by stabilising 
the protein or impeding its interaction with other proteins that facilitate clearance. 
Expansion enhances this interaction and the mutant protein is further stabilised 
resulting in accumulation and aggregate formation. Chen et al. also reported that Akt is 
responsible for ataxin-1‟s phosphorylation at S776. Thus both 14-3-3 and Akt modulate 
neurodegeneration; Akt phosphorylates ataxin-1 promoting its binding to 14-3-3 which 
in turn leads to accumulation of ataxin-1 and neurodegeneration (Chen et al. 2003).  
 
The interaction between ataxin-1 and 14-3-3 proteins has been suggested as a new 
potential target for therapeutic intervention in SCA1 (Umahara and Uchihara 2010). The 
14-3-3 proteins have been shown to be directly involved in SCA1 pathogenesis with 
larger expansions having a higher affinity for 14-3-3 proteins. Ataxin-1 phosphorylation 
is required for the interaction, and 14-3-3 proteins have been found localised to NIIs in 
human SCA1 brain tissue. These highlighted factors point to 14-3-3 as an important 
interacting protein and a possible target for therapy (Umahara and Uchihara 2010).  
 
Recently, de Chiara and colleagues reported the presence of a UHM ligand motif (ULM) 
in the C-terminus of ataxin-1 (de Chiara et al. 2009). This motif has been found in many 
splicing factors and its presence in ataxin-1 points to the protein‟s participation in a 
network of interactions (interactome) involving other splicing factors. An investigation 
into the mechanisms of ataxin-1‟s interactome found that the ULM overlaps both the 
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This region, which also comprises S776, mediates ataxin-1‟s interaction with UHM 
domains of other proteins via the ULM. In its wild-type unexpanded form, un-
phosphorylated ataxin-1 contributes to the spliceosome by interacting with various 
splicing factors via the ULM. The un-phosphorylated form of expanded ataxin-1 
recognises UHM domains despite being unable to bind to 14-3-3. This could protect 
against self-association of the mutant protein allowing its clearance via the proteasome 
pathway. When phosphorylated, the expanded ataxin-1 binds to 14-3-3 altering its 
interactions with the spliceosome and other proteins. The authors suggest that some of 
these changes result in SCA1 disease pathology while other alterations, such as that 
mentioned above, may be protective (de Chiara et al. 2009). 
 
Two important protein modification cellular processes, ubiquitination and 
SUMOylation have also been shown to be important in SCA1 pathogenesis. 
SUMOylation involves a group of proteins (small ubiquitin-like modifiers - SUMO), 
that are covalently attached to target proteins making them resistant to degradation. 
Riley et al. reported that the SUMOylation of ataxin-1 is dependent on the length of the 
polyglutamine tract, phosphorylation at Ser776 and nuclear localisation of the protein 
(Riley et al. 2005). Expansion of the tract resulted in a decrease in SUMOylation which 
may interfere with the role of ataxin-1 as a transcription regulator. 
 
Ubiquitination is a process by which proteins are covalently tagged with ubiquitin 
making them recognisable to the cell‟s degradation machinery (Cummings et al. 1998). 
Ubiquitination involves 3 classes of enzymes, ubiquitin-activating enzyme E1, the 

















Figure 1.1 Pyramidal structure of enzyme interactions in the ubiquitination process. A single 
E1 activates many E2s which in turn interact with several E3s to tag proteins marked for 
degradation.  
 
The enzyme classes (E1, E2 and E3) operate in a pyramidal structure with a single E1 
activating many E2s which subsequently interact with several E3s (figure 1.1), thus 
selective degradation of proteins is mediated by E2s in conjunction with E3s (Hong et 
al. 2008). A study by Hong and colleagues showed that the E2 UbcH6 directly 
ubiquitinates wild-type ataxin-1, demonstrating that UbcH6 and ataxin-1 proteins are an 
E2-substrate pair in the ubiquitin-proteasome system. It is likely that the expanded form 
of the protein disrupts this interaction interfering with the degradation of mutant 
protein and leading to protein aggregation and toxicity (Hong et al. 2008). 
 
A recently characterised protein, sacsin, has been reported to protect against 
polyglutamine-expanded ataxin-1 toxicity (Parfitt el al. 2009). The protein is widely 
expressed in the brain and at particularly high levels in the Purkinje cells, the site of 
SCA1 pathology. It was found to localise with the polyglutamine-expanded ataxin-1 
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Using bioinformatics, the protein was shown to contain a putative ubiquitin-like (UbL) 
domain that co-precipitated with the 20S proteasomal sub-unit, linking sacsin to the 
ubiquitin-proteasome system in which ataxin-1 is known play a role (Hong et al. 2008). 
The protein also contains a J-domain (a feature of DnaJ/Hsp40 proteins), which was 
shown to function with an E.coli Hsp70. This confirms sacsin as a type III Hsp40 
protein. In addition to the domains discussed here, sacsin also contains several regions 
of homology to Hsp90, pointing to a possible chaperone function. It is however, not yet 
clear how sacsin‟s protective function is exerted (Parfitt et al. 2009). 
 
In 1997, Skinner and colleagues reported that normal ataxin-1 localised to several 
nuclear structures while the expanded form localised to a single structure (Skinner et al. 
1997). It has been recently reported that both wild-type and expanded ataxin-1 form 
soluble aggregates whereas other polyQ aggregates are insoluble structures (Krol et al. 
2008). The group used Cos-7 cells transfected with different polyQ proteins fused to 
green fluorescent protein (GFP) to show these differences. Unexpectedly, while other 
polyglutamine-expanded proteins formed aggregates (static structures made up of tightly 
aggregated proteins), both wild-type and expanded ataxin-1 formed multiple nuclear 
accumulations. The ataxin-1 accumulations were found to be SDS-soluble unlike other 
polyQ proteins which were found to be SDS-insoluble. The nuclear accumulations of 
polyglutamine-expanded ataxin-1 were also observed to be more mobile and fused more 
frequently with each other compared to the unexpanded form of the protein (Krol et al. 
2008). The increased dynamics may contribute to pathogenesis by further interfering 
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Ataxin-1 has been shown to associate with the nuclear matrix (Skinner et al. 1997). It is 
likely that the structures containing the expanded form of the protein are less stably 
associated with the matrix which explains the increased mobility (Krol et al. 2008). 
Ataxin-1 is also involved in several previously highlighted processes and pathways such 
as gene transcription and mRNA splicing, any of which may be affected by an increase 
in the nuclear dynamics of the expanded protein, thus contributing to SCA1 
pathogenesis. Krol and colleagues suggest re-defining the observed ataxin-1 structures 
as accumulations rather than aggregates and highlight the importance of understanding 
the nature of these nuclear bodies in both the nucleus and cytoplasm (Krol et al. 2008).  
 
In light of the fact that current data suggests SCA1 pathogenesis occurs via a protein- 
rather than an RNA-mediated mechanism, a model supporting altered protein 
interactions is more likely. Recent work on SCA1 has thus focused on identifying a 
pathogenic gain-of-function exerted by the expanded protein. One approach has been 
to identify proteins that interact with the disease protein under normal and pathological 
circumstances by elucidating the pathways in which ataxin-1 is involved. Figure 1.2 
summarises the main avenues via which the mutant protein is believed to exert its 















Figure 1.2 Possible mechanisms for SCA1 pathogenesis. The central aspect is the expansion 
of the polyglutamine tract. Protein misfolding as a result of polyglutamine expansion is 
believed to lead to impaired protein homeostasis, aggregation and thus neuronal cell 
death. On the other hand polyglutamine expansion has been shown to alter protein-protein 
interactions that may be necessary for cellular homeostasis and finally, ataxin-1 in its 
mutant form may lead to transcriptional dysregulation.  
 
One of the important proteins identified so far is Brother of Ataxin-1 (Boat), a related 
protein that shares the AXH domain of ataxin-1 (Mizutani et al. 2005). Using a Drosophila 
model, Mizutani and colleagues discovered mutant ataxin-1‟s association with Boat 
modulates its cytotoxicity. In a SCA1 mouse model, Boat expression was found to be 
significantly reduced in Purkinje cells prior to the appearance of NIIs and dendritic 
thinning. The reason for this reduced expression is unknown but as an early event in 
SCA1 pathogenesis it could result in increased amounts of self-associated mutant ataxin-
1, thus aggravating the mutant protein‟s toxicity and contributing to cell degeneration 
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In 2006, Lam et al. reported the existence of large stable complexes containing both 
wild-type and expanded ataxin-1 and the transcriptional repressor Capicua (CIC) (Lam et 
al. 2006). Using yeast-two-hybrid assays, it was determined that the interaction occurs 
via the AXH domain of ATXN1 and a conserved region of CIC. Results also showed 
that mutation of the S776 residue of ataxin-1 reduces the amount of expanded protein 
incorporated into ATXN1-CIC complexes. Thus, S776 may play a critical role in 
regulating the formation of these complexes. In a Drosophila model expressing expanded 
human ATXN1, Lam et al. showed a restoration of mutant phenotypes to wild-type by 
co-expressing cic, indicating that Cic protein modulates ataxin-1 toxicity; and that mutant 
ataxin-1 protein interferes with the function of Cic as a repressor in Drosophila (Lam et al. 
2006). From this data, it is clear that the wild-type form of ATXN1 interacts directly 
with CIC and modulates its activity, a function that is partially compromised by 
polyglutamine expansion. It is thus possible that expansion alters the conformational 
state of the protein, which in turn alters the conformational or functional state of the 
ATXN1-CIC complex (Lam et al. 2006).  
 
In 2008, a two-pronged model of SCA1 neurodegeneration was proposed (Lim et al. 
2008). Using a yeast-two hybrid screen Lim and colleagues identified two proteins 
whose interaction with ataxin-1 was dependent on polyglutamine expansion and 
phosphorylation of S776, both of which are critical for SCA1 pathogenesis. The two 
proteins, CIC and RNA-binding motif protein 17 (RBM17), form large distinct 
complexes with ATXN1. Both RBM17 and ATXN1 appear to be involved in the 
regulation of RNA metabolism, thus one potential function of the RBM17-ATXN1 
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As shown in figure 1.3, polyglutamine expansion in ATXN1 enhanced the formation of 
the RBM17-containing protein complex in both cell culture and SCA1 knock-in mouse 


















Figure 1.3 A two-pronged model for SCA1 pathology. In the normal state, there are at least 
two distinct and mutually exclusive ATXN1-associated complexes in vivo. The formation of 
ATXN1-RBM17 appears to require phosphorylation of ATXN1. Polyglutamine expansion in 
ATXN1 favours formation of the RBM17-containing complex, enhancing one endogenous 
function and contributing to neuropathology by a gain-of-function mechanism. 
Concomitantly, expansion decreases formation of the CIC-containing complex, resulting in a 
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Mice lacking the wild-type protein but carrying the mutant form suffered more severe 
symptoms and greater lethality suggesting that wild-type ataxin-1 either protects against 
the mutant protein or is essential for neuronal integrity (Lim et al. 2008). The data also 
suggested that wild-type ataxin-1 competes with polyglutamine-expanded ataxin-1 to 
decrease formation of the toxic RBM17-containing complex (figure 1.3). Thus it is likely 
that the wild-type protein plays a protective role. Another possibility is that the 
ATXN1-CIC complex is neuroprotective. Lim and colleagues also showed that the wild-
type protein is found in the CIC-containing complex while the expanded form 
preferentially forms a complex with RBM17.  
 
The absence of two normal alleles results in an overall lower level of wild-type ataxin-1; 
thus less wild-type ATXN1-CIC complexes are formed, contributing to SCA1 
neuropathology through a partial loss-of-function mechanism as shown in the figure 
(figure 1.3). The repressive activity of CIC was previously found to be greater in the 
presence of the wild-type ataxin-1 than with the expanded protein (Lam et al. 2006). The 
net effect of this reduced activity and the decreased co-repressive activity due to mutant 
ataxin-1 may also contribute to SCA1 pathogenesis (Lim et al. 2008). The authors 
suggest that this dual model may apply just as well to several other dominant 
neurodegenerative diseases caused by a gain-of-function mutational mechanism 
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Using a microarray system, a new study has investigated the difference between gain- 
and loss-of-function mechanisms by comparing the transcriptional defects in the 
cerebella of loss of Atxn1 function mice (Atxn1-/-) to knock-in SCA1 mice (Atxn1154Q/+) 
(Crespo-Barreto et al. 2010). The authors report a number of transcriptional changes 
common to both models, and speculate that these changes may indicate altered 
transcriptional functions of ATXN1 in SCA1 pathogenesis. The study showed that 
most of the transcriptional changes go in the same direction in both Atxn1-/- and 
Atxn1154Q/+ mice, a strong argument that part of the dysregulation in SCA1 might be 
explained by a partial loss-of-function of ATXN1. However, many of the 
transcriptional changes were found to be unique to the knock-in mouse model, which 
could be potentially related to the toxicity of polyglutamine-expanded ataxin-1 (Crespo-
Barreto et al. 2010). Finally, the study demonstrated that over expression of ataxin-1-like, 
a related protein, can rescue some of the molecular and behavioural defects shown by 
the Atxn1-/- mice.  
The authors suggest that ataxin-1 and ataxin-1-like share some normal functions, thus 
ataxin-1-like compensates for loss of ataxin-1 function in mice expressing the 
polyglutamine-expanded ataxin-1. Atxn1L was shown to be a functional homolg of 
Atxn1 in Cic-mediated transcriptional repression (Crespo-Barreto et al. 2010). In 
addition to previous data (Lim et al. 2008), this study supports a two-pronged 
mechanism for SCA1 pathogenesis where enhanced toxic gain-of-function of mutant 
ataxin-1 leads to neurodegeneration, while a simultaneous loss-of-function of other 
endogenous protein complexes (ATXN1-CIC), contributes to the disease phenotype 
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1.5 Introduction to RNAi technology 
In 1998, Fire et al. found that long double-stranded RNA (dsRNA) can be used to 
induce gene silencing in Caenorhabditis elegans (C. elegans) (Fire et al. 1998). Less than ten 
years later, Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or 
Medicine for their work on gene silencing. This discovery has been described as one of 
the major breakthroughs in molecular biology in the last decade and was termed RNA 
interference (RNAi). It is a naturally occurring process conserved in eukaryotes that 
involves the use of small non-coding RNAs to suppress the expression of genes in a 
sequence specific manner. Since its discovery, several different methods have been 
developed to manipulate RNAi for use as both a research tool and as a novel 
therapeutic strategy for the treatment of cancer, infection and neurodegenerative 
disease. By knocking down expression of genes in a sequence-specific manner, RNAi 
can be used to determine gene function as well as the pathogenic mechanisms of various 
diseases. 
 
Small RNAs have been found endogenously expressed in several organisms including 
mammals, Drosophila melanogaster (D. melanogaster) and C. Elegans (Castanotto and Rossi 
2009). Table 1.1 shows further details on these known small RNAs. One group is 
characterised by their interaction with the P-element induced wimpy testis (PIWI) clade 
of Argonaute proteins, and are thus known as PIWI-interacting RNAs (piRNAs). So far, 
these have only been identified in germline cells and originate from transposons, viruses 
and repetitive sequences. More recently another class of endogenous small interfering 
RNAs (endo-siRNAs or esiRNAs) has been identified in the gonads and somatic tissue 
of D. melanogaster and in mouse oocytes. They are proposed to regulate retrotransposon 
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Other small RNA families (Table 1.1) including repeat-associated siRNAs (ra-siRNAs), 
tiny non-coding RNAs (tncRNAs), trans-acting siRNAs (ta-siRNAs) and scan RNAs 
(scnRNAs) have been found in other organisms but as yet, not in mammals (Castanotto 
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Table 1.1 Cellular small RNAs involved in gene silencing 
 
 
endo-siRNAs = endogenous siRNAs, miRNAs = microRNAs, natRNAs = natural antisense transcript RNAs, piRNAs = PIWI-interacting RNAs, ra-siRNAs = repeat-
associated RNAs, scnRNAs = scan RNAs, siRNAs = short interfering RNAs, ta-RNAs = trans-acting RNAs, tncRNAs = tiny non-coding RNAs  
(from Castanotti and Rossi 2009). 
Class Size (nt) Function Mechanisms Origin Organisms found in 








C. elegans, D.  melanogaster, 
Schizosaccharomyces pombe, 
Arabidopsis thaliana, Oryza sativa 
endo-
siRNAs 
21-25 Restricting transposons, 
regulating mRNAs and 
heterochromatin 
RNA degradation Transposable 
elements, 
pseudogenes 
D. melanogaster, mammals 
miRNAs 21-25 Regulating gene 
expression at the post-
transcriptional level 




C. elegans, D. melanogaster, S. 
pombe, A. thaliana, O. sativa, 
mammals 
piRNAs 24-31 Regulating germline 
development and 
integrity, silencing selfish 
DNA 
unknown Defective transposon 
sequences and other 
repeats 




23-28 Remodelling chromatin, 
transcriptional gene 
silencing 
unknown Repeated sequence 
elements (subsets of 
piRNAs) 
C. elegans, D. melanogaster, S. 




21-22 Trans-acting cleavage of 
endogenous mRNAs 
RNA degradation Non-coding 
endogenous 
transcripts 
D. melanogaster, S. pombe, A. 
thaliana, O. sativa 
natRNAs 21-22 Regulating gene 
transcription at the post-
transcriptional level 




scnRNAs 26-30 Regulating chromatin 
structure 
DNA elimination Meiotic micronuclei Tetrahymena thermophila, 
Paramecium tetraurelia 
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In humans, dsRNA is produced by a specific class of regulatory non-coding microRNAs 
(miRNAs). As shown in figure 1.4, synthesis of endogenous miRNAs begins with their 
transcription as primary microRNA (pri-miRNA) transcripts (Lee et al. 2002a). These are 
then processed in the nucleus by the Drosha/DGCR8 complex, into precursor miRNAs 
(pre-miRNAs) that are transported from the nucleus via an exportin-5-dependent 
mechanism (Lee et al. 2003, Yi et al. 2003). In the cytoplasm, pre-miRNAs are processed 
into short molecules by Dicer (an RNase III ribonuclease that generates RNA duplexes), 
approximately 22-nucleotides (nt) long, known as mature miRNAs. Endogenous 
miRNAs suppress gene expression by binding target messenger RNA (mRNA), 
blocking translation and facilitating degradation in processing bodies (P-bodies) (Sheth 
and Parker 2003, Hammond 2005).  
 
One of the ways in which RNAi may be manipulated for gene silencing involves the use 
of artificial dsRNA molecules designed to specifically knock down the expression of 
mutant genes. This is most commonly mediated by siRNAs that are generated by the 
processing of complementary dsRNA templates into 21-23 nt duplexes (figure 1.4). The 
siRNAs consist of an „antisense‟ (complementary to the target gene) and „sense‟ (same 
sequence as the target gene) strand (Meister and Tuschl 2004, Hammond 2005). During 
assembly of the RISC, the siRNA is unwound in a strand specific manner and the 
antisense strand locates mRNA targets by Watson and Crick base-pairing. The antisense 
strand thus determines effective and specific silencing of the targeted mRNA. One of 
the components of RISC is Argonaute 2 (AGO2), an endonuclease which cleaves 
bound mRNA provided it is perfectly complementary to the guide strand (Liu et al. 
















Figure 1.4 The mechanisms of cellular gene silencing. a. In plants and animals, pri-miRNAs are 
processed by Drosha and its partner DGCR8, into pre-miRNAs which are then transported to the 
cytoplasm by exportin 5 (XPO5). In the cytoplasm, pre-miRNAs are bound by a Dicer-containing pre-
RISC and processed to yield the guide strand which is then loaded into holo-RISC (contains all the 
required components for gene silencing, including AGO2 the catalytic core). The guide strand binds 
to its complementary target sequence in the 3’UTR of cellular mRNA. If perfect complementarity is 
achieved (left of diagram), it triggers site-specific cleavage and degradation of the mRNA via the 
catalytic domain of AGO2. If base-pairing is incomplete (right of diagram) but includes pairing of the 
seed region (nucleotides 2-8 of the miRNA) with the target, translational inhibition occurs and may 
lead to non-sequence-specific degradation of the mRNA in P-bodies. b. Similarly to miRNAs, 
artificially transcribed shRNAs (in this case from a plasmid) are transported to the cytoplasm by XPO5 
where the dsRNAs are recognised and processed by Dicer into 21-25 nt siRNAs that are loaded into 
RISC. The siRNAs are designed to target complementary sequences triggering their degradation by 
AGO2-mediated cleavage. c. In the nucleus, complementary siRNAs may trigger chromatin 
remodelling and histone modifications that result in transcriptional gene silencing. In mammalian 
cells, the mechanism involves the Argonaute-family proteins but the details are unclear. TRBP = HIV 
tar-RNA-binding protein, PACT = activator of protein kinase PKR, m
7
G = 7-methylguanosine  
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Several groups working on neurodegenerative disease to achieve targeting of transcripts 
using siRNAs have reported a number of challenges, the most important of which is 
their transient effect (Kim and Rossi 2007). Unlike in C. elegans where siRNAs are 
amplified by RNA polymerases, in mammalian cells which lack these enzymes, the 
effect of synthetic siRNAs is negated soon after the molecules are incorporated into the 
RISC complex (Cullen 2004). Other issues include side effects such as induction of 
interferon response, saturation of the endogenous pathway, delivery to certain systems 
or tissues and off-target effects. Different chemical modifications can be made to 
synthesised siRNAs to improve stability and efficacy and reduce off-target effects but 
they are still only effective in the short-term and require multiple applications (Kim and 
Rossi 2007, Castanotto and Rossi 2009).  
 
Another major challenge with siRNAs is their delivery to the targeted cells and tissues 
since they cannot easily cross the cell membranes (Castanotto and Rossi 2009). 
Currently the main avenues are delivery of chemically modified siRNAs or the use of 
shRNA-encoding genes via recombinant viruses that generate siRNAs. Short hairpin 
RNAs (shRNAs) consist of sense and antisense strands separated by several nucleotides 
that form a non-complimentary loop. The shRNAs are delivered via plasmid or viral 
vectors into mammalian cells under the control of polymerase (Pol) II or III promoters 
(Kim and Rossi 2007). Pol III promoters are used where a high level of constitutive 
expression is required, while Pol II promoters can be used to drive tissue-specific 
expression. The products in both cases are efficiently incorporated into RISC. The use 
of promoter-expressed shRNAs or miRNAs can potentially mediate long-term silencing 
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Targeting diseases of the CNS such as SCA1 further compounds the issue of safe and 
efficient delivery. The CNS is both structurally and functionally complex and is 
insulated from the vascular system by the blood-brain barrier (BBB) and the cerebral 
spinal fluid (CSF)-blood barrier. The use of recombinant viruses circumvents these 
problems since the viral vectors injected directly into the brain can yield expression of 
RNAi effectors driven by a tissue-specific promoter. Viral vectors can also be used for 
integrated permanent expression of the therapeutic gene, a requirement for chronic 
progressive diseases such as the dominant neurodegenerative disorders (Gonzalez-
Alegre and Paulson 2007, Kim and Rossi 2007, Castanotto and Rossi 2009).  
 
An important consideration in the choice of a vector is shRNA integration versus their 
episomal persistence within an expression cassette (Grimm and Kay 2009). Other 
considerations are the virus‟ inherent immunogenicity and the efficacy of the 
recombinant virus in a given cell or tissue. There are currently three major viral vectors 
for RNAi expression, adenovirus (Ad), lentivirus (LV) and adeno-associated virus 
(AAV). In spite of the success of viral delivery in mouse models of disease (Xia et al. 
2004, Harper et al. 2005), major concerns exist pertaining to vector and RNAi safety. 
Viral vectors are potentially immunogenic and the risk of incurring mutations in viral 
sequences resulting in insertional mutagenesis or aberrant gene expression is relatively 
high (Castanotto and Rossi 2009). Other concerns involve the saturation of the RNAi 
machinery and the resultant toxicity, as well as the adverse effects of off-target silencing. 
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A study by Grimm and colleagues evaluated 49 AAV/shRNA vectors directed against 6 
targets in livers of adult mice (Grimm et al. 2006). Thirty six of the 49 resulted in dose-
dependent liver injury and 23 eventually resulted in death. The group proposes a 
competition model between processing of the over-expressed hairpins and endogenous 
miRNA to explain the observed toxicity. Exportin-5, a shared component of the 
miRNA and shRNA pathways, was identified as a limiting factor.  The authors conclude 
that it is essential to monitor and control intracellular shRNA levels in vivo in order to 
achieve stable gene silencing while mitigating adverse effects (Grimm et al. 2006). 
 
In 2008, another group developed shRNAs targeting conserved sequences in human 
HD and mouse HD homolog (HDh) mRNAs (McBride et al. 2008). The study screened 
35 shRNAs in vitro, narrowing the candidate molecules to three for use in in vivo testing.  
In a knock-in HD mouse model, all three reduced HDh mRNA expression to similar 
levels. However, two of the three induced significant neurotoxicity in mouse striatum, 
possibly as a result of the observed higher levels of mature antisense RNA. The same 
sequences placed in an artificial miRNA expression system resulted in similar levels of 
reduced HDh mRNA xpression with significantly reduced neurotoxicity. The authors 
conclude that miRNA-based systems may be more suitable for achieving RNAi in the 
brain (McBride et al. 2008).  
 
A recent review summarises the significant improvements that have been made to 
original synthetic RNAi technologies in order to avoid the associated problems (Sibley et 
al. 2010). Strategies that involve the use of asymmetric interfering RNAs (aiRNAs), 
small internally segmented interfering RNAs (sisiRNAs) and many others, present 
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Further progress in this field is expected to improve the selection and optimisation of an 
effector, thus making therapeutic success more likely (Sibley et al. 2010). 
 
1.6 RNAi and SCA1 
Previously, proposed therapies for SCA1 and the other polyQs have targeted various 
downstream effects and aimed to enhance the solubility and turnover of the mutant 
protein by up-regulating chaperone proteins for example (Bonini and La Spada 2005). 
Prior to RNAi, targeted gene silencing involved the use of antisense oligonucleotide 
(AON) technology and catalytic nucleic acid biology using ribozymes (Wood et al. 2003). 
Ribozymes have been shown to be vulnerable to degradation by ribonucleases. AON 
technology has been useful in certain contexts but is plagued by low efficacy and a lack 
of specificity in mammalian systems. In spite of these disadvantages, AONs theoretically 
have the potential to target all individuals with a polyQ disorder (Scholefield and Wood 
2010). Investigation into this technology is thus on-going. 
 
RNAi as a therapeutic technique has shown tremendous promise in the search for a 
cure. Experiments on SCA1 mouse models have shown reversal of motor abnormalities 
and normalisation of Purkinje cell pathology. Xia and colleagues tested various AAV-
expressed shRNAs targeting different sequences along the mutant transcript. Two of 
the constructs, flanking the CAG repeat, were found to mediate silencing in a cellular 
model and were then evaluated in a transgenic SCA1 mouse model. Results showed the 
elimination of NIIs in transduced cells correlating with improved neuropathology 
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In another study, Zu and colleagues created a conditional SCA1 mouse model 
expressing a SCA1 human transgene (Zu et al. 2004). By suppressing the expression of 
transgenic mutant ataxin-1, SCA1 pathogenesis was shown to be completely reversible 
at early stages of disease and partially reversible even at a late disease stage. It is 
noteworthy however, that the effect of endogenous ataxin-1 was not examined. 
 
Several studies have shown allele-specific RNAi to be effective in amelioration of 
disease phenotype in other polyQ disorders such as HD (Harper et al. 2005) and SCA3 
(Miller et al. 2003, Li et al. 2004, Alves et al. 2008). Data thus supports the development 
of allele-specific silencing as a therapeutic strategy for SCA1. However, experiments are 
required to firstly determine the effect of this kind of treatment on a SCA1 knock-in 
mouse that more closely models the human condition, and secondly, on non-human 
primates to adjust the dosage required for the human cerebellum (Gonzalez-Alegre and 
Paulson 2007).  
 
It is also important to note that although the function of wild-type ataxin-1 is unknown; 
its absence has been shown to cause a degree of neurological impairment in Sca1 null 
mice (Matilla et al. 1998). These mice do not display any ataxia or major motor 
coordination abnormalities but they do show neurobehavioural abnormalities such as 
decreased exploratory behaviour and impaired performance on the rotor rod. It would 
be preferable to specifically target the mutant transcript with minimal knock-down of 
the wild-type using allele-specific RNAi. However, since mice lacking ataxin-1 show 
only subtle abnormalities it is possible that knockdown of both alleles in SCA1 patients 
may not result in major adverse effects as a result of loss of gene function (Matilla et al. 
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In 2008, Alves and colleagues reported the success of an allele-specific siRNA silencing 
strategy for SCA3 by targeting a single nucleotide polymorphism (SNP) in linkage 
disequilibrium with the disease-causing expansion in 70% of SCA3 patients (Alves et al. 
2008). The approach developed used LV vectors encoding shRNAs to selectively target 
the mutant allele in a rat model of SCA3. More recently, this group has also investigated 
the global silencing of ataxin-3 with positive results (Alves et al. 2010). 
 
1.7 South African perspective 
A recent study has found that there may be success in applying an RNAi-based 
therapeutic approach for SCA7 patients in South Africa (Scholefield et al. 2009). All the 
SCA7 patients identified by the Human Genetics Division at the University of Cape 
Town (UCT) share the same haplotype, with a well-characterised SNP linked to the 
disease-causing expansion (Greenberg et al. 2006). With over 50% of patients 
heterozygous for this SNP, it provides a single nucleotide difference with which to 
discriminate between the wild-type and mutant transcripts. The study investigated allele-
specific RNAi by targeting short sequences of ATXN7 tagged to luciferase reporters, or 
full-length ATXN7 cDNAs tagged to fluorescent reporter genes. An allele-specific 
effector was identified that has little effect on the wild-type protein and achieves strong 
silencing of the mutant. This suggests that targeting a single base pair difference, 
heterozygous in a significant number of patients, specifically where a founder effect 
exists, may be useful (Scholefield et al. 2009).  
 
In 1997, a study was performed on 6 large SCA1 kindreds using three microsatellite 
markers D6S260, D6S89 and D6S274 (Ramesar et al. 1997). The authors reported the 
existence of two distinct founder effects in the Mixed Ancestry population in the 
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This study thus proposes a similar approach as that used for SCA7 (Scholefield et al. 
2009); that is to develop a novel RNAi therapy for SCA1 in South Africa by targeting a 
single nucleotide difference linked to the disease-causing expansion.  
 
1.8 Aims and Objectives 
1.8.1 Aims 
Allele-specific silencing has been used to target a linked SNP in the South African SCA7 
patient population where a founder effect exists. It is proposed that the SCA1 patient 
population may also benefit from such an approach. Although the function of the 
ataxin-1 protein is not clearly defined, it is thought to play an essential role in cellular 
function, thus a method of preserving the wild-type protein would be desirable. As 
previously mentioned, two founder effects have been shown to exist in a specific 
population of South Africa. With advances in molecular genetics, the discovery of SNPs 
makes it possible to confirm the reported founder effects using SNPs in and around the 
ATXN1 gene, instead of microsatellite markers. A SNP-based haplotype is more 
informative because of the increased availability of markers which makes it possible to 
narrow the region of analysis. In addition, genotyping SNPs may identify single 
nucleotide differences between the mutant transcript of ataxin-1 and its normal 
counterpart that may be potential targets for allele-specific RNAi.  
 
Thus the aims of this project are firstly, to construct a more informative SNP-based 
haplotype to confirm the reported founder effects and secondly, to identify appropriate 
single nucleotide differences between the wild-type and mutant alleles of ATXN1 and 
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1.8.2 Objectives 
In order to achieve the above stated aims, the following objectives have been outlined: 
A. Use SNP genotyping to identify possible founder haplotypes for the disease-
causing allele. 
B. Identify a SNP with sufficient heterozygosity in the patient population. 
C. Design and screen tiled shRNAs against the wild-type and mutant targets in vitro 
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2. Materials and Methods 
SECTION I: Construction of a SNP-based haplotype 
around the SCA1 locus  
The Human Genetics Division at the University of Cape Town (UCT) has since the 
1980s been involved in the collection of DNA samples from individuals clinically 
diagnosed with neurodegeneration. Informed consent (appendix C) was obtained and 
blood samples taken. DNA was isolated according to the protocols of the PUREGENE 
DNA Isolation Kit (Gentra Systems) outlined in “Rapid DNA isolation from 300 µl whole 
blood” or “DNA isolation from buffy coat prepared from 300 µl whole blood”. Each 
DNA sample was assigned a laboratory reference code to ensure confidentiality, and 
available patient and family information was recorded onto the Microsoft Access 
Human Genetics Division Laboratory database.  
The DNA samples were stored at -20°C for short term storage or at -80°C for long 
term storage. 
 
As mentioned in Chapter 1, a previous study performed on six large SCA1 kindreds 
reported two distinct founder effects in the Mixed Ancestry families from the Western 
Cape (Ramesar et al. 1997). In this section, individuals from these kindreds were 
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2.1 Selection of families for SNP haplotyping 
In order to establish which haplotypes are associated with the disease-causing expansion 
in the Mixed Ancestry SCA1 population, a cohort of individuals was selected. The main 
criterion used was the presence of a complete triad, two parents (one of whom was 
affected) and an affected child. Eight triads were identified in five of the six Mixed 
Ancestry SCA1 families from the previous study, and individuals genotyped for their 
CAG repeat lengths and the selected SNPs. 
 
2.2 Molecular genetic test for SCA1 
Due to the instability of the expanded CAG repeat, different cells/tissues in an affected 
individual may carry alleles with slightly different repeat lengths. This makes the sizing 
of repeats somewhat subjective. Thus in order to confirm the affection status of 
individuals and the length of the CAG tract for purposes of this study, a PCR-based 
molecular genetic test was performed. DNA aliquots were taken from the stored stock 
samples and diluted to approximately 100 ng/µl concentration.  
 
2.2.1 Polymerase chain reaction (CAG repeat) 
PCR was performed using published primers (Dorschner et al. 2002) (appendix A) 
obtained from the molecular diagnostic laboratory in the Human Genetics Division, 
UCT. The PCR was performed as a standard reaction (appendix C), with the following 
thermal cycling conditions: 1 cycle of initial DNA denaturation at 95°C for 3 minutes; 
28 cycles of (denaturation at 95°C for 60s, annealing at 61°C for 60s, elongation at 72°C 
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2.2.2 Agarose gel electrophoresis 
To confirm amplification, PCR products were resolved by electrophoresis through a 2% 
w/v agarose gel stained with ethidium bromide (EtBr) (Sigma-Aldrich) (appendix B). 
Ethidium bromide intercalates with DNA and fluoresces under ultra-violet (UV) light 
enabling visualisation of the DNA.  
 
Cautionary note: Ethidium bromide has mutagenic properties. Care must be taken 
when working with this compound to ensure no skin contact. Wear impermeable 
gloves, a laboratory coat and other laboratory safety equipment where necessary. 
 
Five microlitres of each PCR product were combined with 3 µl of agarose gel loading 
buffer (appendix B), loaded on to the gel and electrophoresed in 1 x Tris Borate-EDTA 
(TBE) buffer (appendix B) at 120 volts (V) for approximately 30 minutes. A size 
standard, GeneRulerTM 100bp Plus DNA Ladder (Fermentas, appendix C) was 
electrophoresed alongside to enable size estimation of the PCR products. After 
electrophoresis, the DNA was visualised under UV light using the uvipro gel 
documentation system (uvitec) and photographed by uvipro software (uvitec).  
 
Cautionary note: Ultra-violet light degrades DNA. It is important to minimise 
exposure particularly if the DNA is to be used in any downstream experiments. Care 
must also be taken to avoid exposure to UV light, especially of the eyes. Wear 
impermeable gloves, a laboratory coat and goggles.  
 
2.2.3 Genotyping on the 3100 ABI Genetic Analyzer 
Once amplification was confirmed, PCR products were resolved on the ABI 3100 
Genetic Analyzer (Applied Biosystems) to enable size estimation and subsequent repeat 
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PCR products were prepared in a 96-well microtitre plate as follows: 1 µl PCR product, 
0.3 µl Gene Scan ROX500 size standard (Applied Biosystems) and 8.7 µl Hi-Di formamide 
(Applied Biosystems) were added to each well. The mixture was denatured for 3 minutes at 
95°C on a Touchdown Thermal Cycler (ThermoHybaid) and immediately cooled on ice 
prior to capillary based electrophoresis on the ABI 3100 Genetic Analyzer (Applied 
Biosystems). Results were collected using ABI PRISM 3100 Data Collection Software 
(v1.1, Applied Biosystems). Analysis of the raw data was performed using GeneMapper 
Software (v3.0, Applied Biosystems). Normal allele sizes were recorded. The sizes of the 
expanded alleles were estimated from the largest peaks visualised using GeneMapper.  
 
The formula below was used to calculate the number of CAG repeats in each allele:  
[(amplicon size – 163)/3 * 1.0678] + 1.115 
This formula is used to adjust for anomalous migration of amplicons during capillary 
electrophoresis (Dorschner et al. 2002). 
 
2.2.4 DNA sequencing 
Several PCR products were randomly selected and sequencing performed to confirm the 
repeat sizes obtained by genotyping above.  
Twenty microlitres of PCR product were combined with 3 µl of loading buffer, loaded 
onto a 2% w/v agarose gel stained with EtBr and electrophoresed in 1 x TBE for 30 
minutes at 100V. The DNA was visualised under UV light and the bands quickly 
excised using a clean scalpel. The gel blocks were put into 1.5 ml eppendorf tubes and 
DNA extracted according to the manufacturer‟s protocol (appendix C) using the 
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Three microlitres of purified extract were combined with loading buffer and 
electrophoresed to confirm minimal loss of DNA during gel extraction. Cycle 
sequencing (appendix C) was performed on the extracted DNA in the 5‟ to 3‟ direction 
using the ABI PRISM BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems). (The SCA1 R primer (appendix A) carries a fluorescent tag, 6-FAM, and thus 
could not be used for sequencing).  
 
Products of the cycle sequencing reaction were then purified by ethanol precipitation 
(appendix C) prior to resolution on the ABI PRISM 3100 Genetic Analyzer (Applied 
Biosystems). Results were collected using ABI PRISM Data Collection Software (v1.1, 
Applied Biosystems) and analysed using Sequencing Analysis Software (v3.7, Applied 
Biosystems). Electropherograms were examined manually using BioEdit Sequence 
Alignment Editor (v7.0.5.2, Hall 1999). The CAG repeats were counted and compared 




















Page | 38  
 
2.3 SNP selection  
To construct a SNP-based haplotype around the CAG repeat region in ATXN1, SNPs 
were selected using the following online databases: Entrez SNP in the National Centre 
for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov) and 
the Ensembl Genome Browser database (http://www.ensembl.org). A chromosomal 
region of approximately 450 kb spanning the ATXN1 gene (6p23) was investigated for 
the presence of SNPs. The region was kept relatively small in order to reduce the 
probability of recombination events. SNPs were chosen according to the following 
criteria: a heterozygosity value approaching 50% and a minimum minor allele frequency 
(MAF) value of less than 10%. Heterozygosity values lower than 25% greatly reduce the 
chance of a triad within the same family yielding informative, in-phase genotypes. The 
MAF is indicative of a SNP‟s diversity in the population. The selection criteria were 
applied to data from both European and Yoruba populations in an attempt to represent 
the Mixed Ancestry population.  
 
Table 2.1 shows the SNPs selected according to these criteria. Figure 2.1 shows the 
positions of the selected SNPs along the ATXN1 gene, as well as one of the 
microsatellite markers used in the previous study and the position of the CAG repeat 
relative to the SNPs. The alleles indicated in the table are reference alleles from the 
NCBI website, according to the reverse sequence. However, note that sequencing is 
performed in the 5‟ to 3‟ (forward) direction and thus sequencing results are the 
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Table 2.1 SNPs selected for construction of a SNP-based haplotype 
SNP RefSNP accession ID Reference alleles Chromosomal location* 
1 rs471716 C/T 6:16763242 
2 rs4716071 A/ G 6:16433223 
3 rs2075974 A/ G 6:16327330 
4 rs180017 C /T 6:16306202 
5 rs1042427 C /T 6:16295555 
*taken from contig NT_007592.15, Genome Build: 37.1 (NCBI) 






Figure 2.1 Positions of the selected SNPs along the ATXN1 gene. Highlighted in RED is the 
position of the expanded CAG repeat, (CAG)n. Highlighted in YELLOW is the position of the 
microsatellite marker D6S274, used in the previous study (Ramesar et al. 1997). The gene is 
transcribed in reverse, right to left of the figure as indicated by the blue arrow; the selected 
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2.4 SNP genotyping  
In order to genotype the selected SNPs, it was necessary to design primers, perform 
PCRs and select a method for genotyping. Restriction enzyme digestion and single-
strand conformational polymorphism analysis were used to determine SNP genotypes. 
 
2.4.1 Primer design 
Primers were designed to amplify the sequence of DNA spanning the SNP to be 
genotyped. The process of primer design was carried out as outlined: 
 Primer3 (v.0.4.0, Rozen and Skaletsky 2000) was used to select possible primers 
from the sequence under investigation. The parameters were: length between 18 
and 23 bp and melting temperature (Tm) between 50° and 58°C. 
 The melting temperatures of each primer pair were calculated using 
OligoCalculator (Buehler, 1992) and matched to within 1°C of each other by 
manual adjustment of the primer length. The 3‟ end of each selected primer was 
either a “G” or a “C” nucleotide to enhance binding specificity. 
 The potential of the primers to form secondary structures (hairpins, 
homodimers and heterodimers) was tested using OligoAnalyzer (v3.0, Integrated 
DNA Technologies). 
 Finally primer sequences were subjected to a genome-wide sequence similarity 
search using the NCBI BLAST (Basic Local Alignment Search Tool: comparing 
nucleotide sequences, at http://blast.ncbi.nlm.nih.gov/Blast.cgi ). This was to 
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2.4.2 Polymerase chain reaction (SNPs) 
PCRs were performed to amplify the target regions spanning each SNP. Optimisation 
for yield and specificity was carried out by altering one or more of the following 
parameters of the standard reaction (appendix C): annealing temperature (Ta), 
Magnesium Chloride (MgCl2) concentration and thermal cycling conditions. For each 
PCR, the optimal Ta was determined with a temperature gradient experiment. The 
gradient started at least 5°C below and up to 5°C above the Tm of the primers as 
calculated by OligoCalculator. PCR products were electrophoresed and visualised as 
previously described. The optimal Ta was determined as the temperature at which the 
desired product yield was highest (brightest band) and showed the least amount of non-
specific amplification (other bands). Where further optimisation was necessary, a MgCl2 
titration experiment was set up with the PCR containing 1 x Reaction Buffer without 
MgCl2  (Invitrogen) and 50 mM MgCl2 (Invitrogen) at final concentrations of 0.5 mM, 1 
mM, 1.5 mM, 2mM and 2.5 mM in the total reaction volume. Thermal cycling 
conditions were also adjusted where necessary; longer annealing and elongation times 
and more cycles yielded more product. 
 
Table 2.2 shows the primer sequences for each selected SNP, their optimal annealing 
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Table 2.2 Details of PCRs for amplification of SNPs 
SNP Primer sequences Ta Expected amplicon size 
(bp) 
SNP1 F 5’ GTCCACTAGAGGCTGTAATG 3’ 
R 5’ CTAAGTGTCTGGAAACATGATC 3’ 
58°C 438 
SNP2 F 5’ GAAATCTGCATGGAAGCCTG 3’ 
R 5’ CTGTTTCTAGATCTGATGCAC 3’ 
58°C 295 
SNP3 F 5’ CTACAGCAGTCGTGATCCTTC 3’ 
R 5’ CTGTGTGTGGTCTGAATGAC 3’ 
58°C 210 
SNP4 F 5’ ACGAGTGTCTGTCAGTGAG 3’ 
R 5’ TGAAGCTGGGTTCCTGATG 3’ 
56°C 361 
SNP5 F 5’ TCAGCAGGAGGGCAACATTC 3’ 




2.4.3 Restriction endonuclease digestion 
SNPs 1, 3, 4 and 5 were genot ped by restriction endonuclease (RE) digestion. The 
restriction enzymes used were determined by analysis of each SNP amplicon using 
Webcutter 2.0 (Heiman, 1997). Table 2.3 shows the SNPs that were genotyped by RE 
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Expected RE digestion products 
(bp) 
SNP1 (C/T) 438 C allele: 370 bp and  
68 bp* 
T allele: 212 bp,  
158 bp and 68 bp* 
SNP3 (A/G) 210 A allele: 210 bp G allele: 107 bp and  
103 bp 
SNP4 (C/T) 361 C allele: 361 bp T allele: 185 bp and  
176 bp 
SNP5 (C/T) 296 C allele: 171 bp,  
94 bp and 31 bp* 
T allele: 232 bp and  
64 bp* 
*Fragment too small to visualise on an agarose gel 
Note that the indicated alleles are from the reverse genomic DNA sequence 
 
 
Table 2.4 gives the details of the RE digestions performed for each SNP. The amount 
of PCR product, the restriction enzyme used and the incubation temperature are shown. 
Each restriction digestion contained 5 units of the respective enzyme in a total volume 
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Table 2.4 Set-up of RE digestions for SNPs 1, 3, 4 and 5  






*SNP1 7 AluI 37 
SNP3  10 StuI 37 
*SNP4  10 AvaII (Eco47I) 37 
*SNP5  7 BslI 55 
*After 1 hour of incubation, another 5 units of enzyme were added to the RE digestion and 
incubated overnight 
 
Subsequent to RE digestion, 10 µl from each digestion were combined with 3 µl of 
agarose gel loading buffer, and electrophoresed through 2% w/v agarose gels as 
previously described. A size standard was electrophoresed alongside the digest products 
to enable size estimation. The gels were visualised under UV light and photographed as 
previously described. 
 
SNP2 did not show a suitable variation at any restriction sites and was therefore 
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2.4.4 Single-strand conformational polymorphism (SSCP) analysis 
Genotypes for SNP2 were determined using SSCP analysis.  
PCR was performed as a standard reaction (appendix C) with thermal cycling conditions 
adjusted as follows: 1 cycle of initial DNA denaturation at 95°C for 3 min;  
25 cycles of (denaturation at 95°C for 15s, annealing at 58°C for 15s, elongation at 72°C 
for 45s); 1 cycle of final elongation at 72°C for 5 min. The shorter denaturation and 
annealing times served to reduce the amount of product from the reaction, giving 
clearer patterns for SSCP analysis. 
 
Two 22 cm by 12 cm glass plates were cleaned thoroughly, first with ethanol and then 
with acetone. Plate glue was applied to the back plate to ensure that the gel matrix 
would stick to the plate (the front plate had blocks of Dyma tape used for well 
formation). A 0.5 mm spacer was sandwiched between the two plates. A 12% non-
denaturing polyacrylamide gel solution was made, consisting of 5.3 ml of 40% w/v 
Acrylamide-piperazine diacrylamide (PDA) solution (appendix B), 8.5 ml of 0.75M Tris-
formate buffer (appendix B) and 3 ml of 41% v/v glycerol.  
 
Cautionary note: Acrylamide is a potent neurotoxin and irritant. Care must be taken 
to avoid any skin contact with, or inhalation of this compound. Wear the necessary 
laboratory safety equipment – laboratory coat, goggles, a mask and two pairs of 
impermeable gloves when working with this compound. 
 
Polymerisation of the gel solution was achieved by adding 200 µl of 10% w/v 
ammonium persulphate (APS) (appendix B) and 20 µl of N‟N‟N‟N‟-
tetramethylethylenediamine (TEMED) (BDH Laboratory Supplies). The total volume was 
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After separation of the plates, the back plate (gel plate) was placed on the LKB 2117 
Multiphor II Electrophoresis Unit (Pharmacia Biotech). For each gel, 6 filter strips 
(approximately 25 cm x 5 cm) were soaked in 1 x Tris Borate (TB) buffer (appendix B) 
and 3 strips overlaid on each side of the gel. The PCR products were diluted 10-fold. 
One microlitre of the diluted PCR product was combined with 3 µl of SSCP loading 
buffer (appendix B) and loaded into the wells in the gel. Electrophoresis was performed 
at 5°C for 2 hours at 355 V using the Multiphor unit (Pharmacia Biotech). 
 
The gels were then rinsed in distilled water to remove excess buffer. DNA was 
visualised by silver staining carried out as outlined. The gels were firstly incubated in a 
0.1% w/v silver nitrate solution (appendix B) for 15 minutes, and then rinsed 
thoroughly with distilled water to remove any excess solution. Thereafter, they were 
incubated in a solution containing 0.375M sodium hydroxide and 0.8% v/v 
formalydehyde (appendix B) for 5-10 minutes until the staining was sufficiently 
developed. The gels were photographed using a digital camera. 
 
2.4.5 DNA sequencing for SNP2 
DNA sequencing was required to distinguish between the patterns shown by SSCP 
analysis and determine their particular genotypes. Sequencing was performed as 
previously described with two modifications. Firstly, the PCR products were sequenced 
directly without gel extraction as they are specific to the region of interest; and secondly 
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2.4.6 Family studies  
In order to complete the construction of the haplotypes in the 5 families, several 
additional family members were genotyped. This was necessary to establish phase for 
some loci, due to uninformativity and missing genotypes. A total of 41 individuals from 
the 5 families, comprising 27 affected subjects, were genotyped for the construction of 
the SNP-based haplotype. Family pedigrees were drawn using Cyrillic software (v2.1). 
Segregation analysis was used to infer genotypes where necessary; and to construct 
haplotypes for each individual. 
 
2.5 Statistical analysis 
Statistical analysis was performed using anonymous control DNA samples from 
individuals of Mixed Ancestry origin available in the Human Genetics Division (UCT). 
Controls are ideally asymptomatic and are sourced from the general population. DNA 
samples from these controls were genotyped and used to establish whether Hardy-
Weinberg equilibrium (HWE) exists for the selected SNPs; and to exclude the 
possibility of the disease-associated haplotype occurring at a high frequency in the 
background Mixed Ancestry population. 
 
2.5.1 Application of Hardy-Weinberg equilibrium  
The phenomenon of HWE was first described in 1908. In the absence of migration, 
mutation, natural selection and assortative mating, genotype frequencies at any given 
locus are a simple function of allele frequencies (Wigginton et al. 2005). A deviation 
from HWE at a given marker suggests a change in population structure such as 
inbreeding, population stratification or it may indicate genotyping problems. In a sample 
of affected individuals, deviation from HWE suggests an association between the 
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It is a well-established practice to check whether observed genotypes conform to Hardy-
Weinberg expectations. For a locus with two alleles: A and C, with frequencies p and q 
respectively, where p + q = 1, HWE exists when: 
p2 + 2pq + q2 = 1. 
The expected frequencies of the genotypes AA, AC and CC are p2, 2pq and q2 
respectively. A chi-squared test is normally used to indicate whether the data is 
significantly in disequilibrium. The null hypothesis is that the frequencies are in HWE, 
and is approximated with a continuous distribution. For a small sample size and discrete 
data such as genetic markers (Rohlfs and Weir, 2008), an exact test rather than a chi-
squared test is required to make a more accurate analysis possible. An online webpage, 
http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl was used to perform the 
Hardy-Weinberg exact test to determine whether SNP genotype data fits HWE in the 
Mixed Ancestry population group. 
 
2.5.2 PHASE analysis 
The founder haplotypes identified in the Mixed Ancestry population (Ramesar et al. 
1997) were investigated in the background population. For phase-unknown data from 
the unrelated controls, it was necessary for haplotypes to be inferred. This may be 
difficult due to the number of possible haplotypes which increases as a power of 2 with 
each additional SNP included in the analysis (Adkins, 2004). Several programs are 
available for this kind of analysis and have been shown to be highly accurate. PHASE 
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PHASE (v2.1) is freely available at http://www.stat.washington.edu/stephens/software. 
The program uses a Bayesian statistical method to reconstruct haplotypes from 
population genotype data and is able to deal with SNP, microsatellite and other multi-
allelic loci in any combination, as well as missing data. The Bayesian method treats 
unknown haplotypes as random quantities and combines previous information (what 
kind of patterns one would expect in a population sample), with the probability of the 
haplotype in the observed data (Stephens and Donelly, 2003). In this way it is possible 
to calculate the conditional distribution of the unobserved haplotypes (or haplotype 
frequencies) given the observed genotype data. 
 
The format of the input file is explained in detail in the instructions in the program 
package. The input file specifies how many individuals are to be analysed, how many 
loci each individual has been genotyped at, the type of loci (SNP or microsatellite) and 
the genotype at each. PHASE uses an iterative scheme to perform inference. Parameters 
to control the number of iterations performed can be added to the input line, otherwise 
default values are used. The basic command line is as follows: 
./phase <filename.inp> <filename.out> 
 
Analysis was performed separately on the affected individuals and the controls 
respectively, using the following commands: 
 phase -s500 -f1 -kknown.txt patientonly.inp patientonly.out  
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The command line begins with “phase” which is used to invoke the program. The –s 
option is used to set the value of the seed of the pseudo-random number generator and 
must be a positive integer. To obtain reliable results, it is advisable to run the algorithm 
several times with different seeds and then check consistency across runs. The –f option 
specifies the format of the input file, -f1 indicates that genotypes are listed on a single 
line for each individual. The –k option allows the user to specify known phases; 
“known.txt” is the file containing this information for the affected individuals. The 
command lines also specify the input files (“patientonly.inp” and “cononly.inp”) and 
their respective output files. The program gives several output files, the first of which is 
a summary of the haplotype estimates for each individual. The other files give detailed 
results and estimates of the sample haplotype frequencies which is the required output 
in this case.  
 
In this study, PHASE analysis was performed on the controls in order to determine the 
frequency of the identified disease-associated haplotypes. The haplotypes frequencies 
were then extrapolated to estimate the frequencies in the background population. 
Analysis was also performed on the patients in order to provide a more direct 
comparison of haplotype frequencies between the two groups, and to serve as a control 
by ensuring that the program selected the correct disease-associated haplotypes 
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SECTION II: Allele-specific silencing 
The use of allele-specific silencing for dominantly inherited disorders has shown some 
success. This approach may be particularly useful where a founder effect exists such that 
the disease-causing mutation is linked to a single SNP in a large number of affected 
individuals (Scholefield et al. 2009). In section I, a SNP-based haplotype was constructed 
and two SNPs were identified with greater than 50% heterozygosity in the SCA1 
affected individuals. Short hairpin RNA effector molecules were designed against targets 
incorporating the selected SNP. Subsequently a dual luciferase reporter assay was used 
to screen the shRNAs in order to test the feasibility of this SNP as a target. The flow 
diagrams below outline the steps performed. 
 
 
2.6 Plasmid construction/cloning (shRNA) 
In order to construct a shRNA-expression system, several steps were performed as 
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2.6.1 Effector design  
The shRNA effector molecules were designed based on the original expression vector 
system developed by Brummelkamp and colleagues (Brummelkamp et al. 2002). Their 
system used a Pol III promoter which produces small transcripts with a well-known 
start site and a five thymidine (T) termination signal. For this study, a U6 Pol III 
promoter from a pTZU6+1 vector (Lee et al. 2002b) was used to drive the production 
of small transcripts. The effectors were designed with 19 nucleotides (nt) 
complementary to the target sequence, defined as the antisense/guide strand; followed 
by another 19 nt of reverse complementary sequence, the sense/passenger strand 
(appendix A – oligos for shRNA construction). This sequence as interrupted by a 9 nt 
loop sequence (the miR-122 loop sequence). The antisense strand terminates with five 
Ts that result in a 2 nt 3‟ overhang because termination site cleavage occurs after the 
second U in the transcript (in the mRNA transcripts, genomic Ts are transcribed to Us 
and not As) (Baer et al. 1990). The favoured thermodynamics of the entire sequence 
predict the formation of a short hairpin loop when transcribed (see generalised structure 
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Cleavage of this dsRNA structure (figure 2.3) by Dicer is expected to yield the 21 to 22 
nt RNA duplexes shown in figure 2.4 below. In order to bias antisense strand selection 
and incorporation into RISC, functional asymmetry was introduced by creating G:U 
wobbles with the addition of mismatches in the 3‟end of the sense strand (Schwarz et al. 
2003). Based on the predicted antisense strand, mismatches to the wild-type allele were 
introduced consecutively from position 9 to position 16; where position 1 is defined as 
the first nt of the 5‟ end of the antisense strand assuming a 21 nt duplex.  
 
 
Figure 2.4 Panel of predicted siRNA molecules designed for allele-specific silencing. The 
target SNP is highlighted in red. Destabilising G:U wobbles are in blue. The underlined 
sequence is the predicted antisense (guide) strand designed to be perfectly complementary 
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2.6.2 Single-step plasmid PCR  
Castanotto et al. describe a method for the construction of shRNA-expressing vectors in 
which the pTZU6+1 plasmid is used as a template to create U6/shRNA cassettes 
(Castanotto et al. 2002). This method was modified using a single-step PCR in order to 
construct U6/shRNA cassettes.  
The single-step PCR was set up as follows: 50 pg of pTZU6+1 plasmid, 10 pmol U6+1 
universal F primer (appendix A), 10 pmol long oligo R primer for each construct 
(appendix A), 0.2 mM dNTPs (Bioline), 1 x GoTaq Buffer (Promega), 2 units GoTaq 
(Promega); made up to a final volume of 25 µl with sH2O. Thermal cycling conditions 
were as outlined (appendix C) with Ta of 60°C. To confirm amplification, 5 µl of the 
PCR products were combined with 3 µl of loading buffer, electrophoresed through a 
2% w/v agarose gel and visualised as previously described.  
 
2.6.3 Ligation 
The PCR products (U6/shRNA cassettes) were ligated into the TA cloning vector, 
pGEM T-Easy (figure 2.5) using the pGEM T-Easy cloning kit (Promega). Ligation 
reactions were set up according to the manufacturer‟s instructions (appendix C) and left 




































Figure 2.5 Diagram of pGEM®-T Easy Vector (Promega) showing the lacZ gene, the 
Ampicillin resistance (Ampr) gene and the multiple cloning sites (www.promega.com). 
 
 
2.6.4 Competent cells 
Cloning is a technique that uses competent bacterial cells to replicate DNA of interest 
for use in subsequent experiments. Competency refers to the cells‟ ability to “take up” 
DNA under specific conditions, a process known as transformation. Thereafter, the 
transformed cells (transformants) are plated on suitable medium to encourage growth 
and colony formation. The resulting colonies serve as a source of the DNA of interest. 
All cloning experiments were performed using the Escherichia coli (E. coli) bacteria strain 
DH5α.  Competent DH5α cells were prepared and stored at -80°C for use in the 
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2.6.4.1 Preparation of competent cells 
DH5α cells were used to inoculate 5 ml of Luria broth (LB) (appendix B) in 15 ml 
Falcon tubes. The tubes were loosely capped to allow aeration and incubated overnight 
at 37°C with vigorous shaking. This starter culture was subsequently diluted 1/100 in 25 
ml LB in 250 ml conical flasks and incubated for 1-2 hours at 37°C until log phase. The 
flasks were loosely covered with foil to allow aeration. Log phase was determined on a 
spectrophotometer by an O.D. reading of between 0.2 and 0.4 at 600 nm. The culture 
was transferred to 50 ml Falcon tubes and the cells collected by centrifugation 
(Beckman J2-21 centrifuge, BeckmanCoulter) at approximately 5000 rpm for 5 minutes at 
4°C. Note: Cells were kept on ice for all further steps.  
The cells were then re-suspended in half of the culture volume, ice-cold sterile 0.1M 
CaCl2 and held on ice for 2 hours. The cells were centrifuged again and gently re-
suspended in one tenth of the original culture volume, ice-cold sterile 0.1M CaCl2. The 
cells were held on ice for a further 30 minutes then aliquoted (500 µl in 1.5 ml 
eppendorfs) and mixed with glycerol to a final concentration of 10% v/v. The aliquots 
of competent cells were labelled and stored at -80°C.  
 
2.6.4.2 Transformation of competent cells 
This method of preparation above is anticipated to produce cells with a transformation 
efficiency of approximately 1 x 107, suitable for most cloning experiments. It is 
important to calculate the transformation efficiency of competent cells in order to 
ensure successful cloning. This may be determined by transforming the competent cells 
with pUC19 plasmid DNA as follows: 100 µl of competent cells were combined with  
1-10 ng of pUC19 plasmid DNA in 1.5 ml eppendorf tubes and held on ice for 30 
minutes. A control tube with 100 µl of competent cells but no DNA was subjected to 
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The cells were heat-shocked at 42°C for 90 seconds and immediately transferred to ice 
for 2 minutes. Nine hundred microlitres of LB were then added and this mixture was 
incubated for 1 hour at 37°C in a shaker to allow expression of the antibiotic resistance 
gene. After incubation 100 µl each from the “expression mix” and the control were 
plated onto selective agar, and incubated at 37°C overnight.  
 
Selective agar plates (appendix B) contain an antibiotic to facilitate the selection of 
positive transformants which form colonies due to the resistance conferred by the 
plasmid. Transformation efficiency was then calculated as follows:  
number of colonies on plate/ng of DNA plated x 1000 ng/µg. 
 
2.6.5 Transformation 
Fifty microlitres of competent cells were combined with 5 µl of the ligation reaction 
products (U6/shRNA cassettes ligated to pGEM T-Easy) from section 2.6.3. 
Transformation was performed as previously described. Thereafter, 950 µl of LB were 
added to each tube and the tubes incubated. 
 
2.6.6 Plating 
The plasmid (pGEM®-T Easy, figure 2.4) carries the lacZ gene which encodes the α 
subunit of the β-galactosidase gene, while the host cells (DH5α) carry the gene encoding 
the γ subunit. Together the gene products form functional β-galactosidase enzyme that 
catalyses 5-bromo-4chloro-3-indolyl-β-Dgalactopyranoside (X-gal) (Roche) to an 
insoluble blue product.  Ligation of DNA into the plasmid interrupts the lacZ gene such 
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All cells transformed with plasmid form colonies (ampicillin resistance conferred by 
plasmid). However, only those transformed with plasmid correctly ligated to the 
U6/shRNA cassette give white colonies.  This serves to distinguish positive 
transformants, a technique known as blue/white screening.  
 
Prior to plating, 40 µl of a 20 mg/ml solution of X-gal were spread on each plate to 
facilitate blue/white screening. Plates were allowed to dry in an incubator at 37°C. One 
hundred microlitres of the expression mix from each ligation were then spread on 
plates, which were incubated at 37°C overnight and then refrigerated for 4-5 hours to 
develop the blue colour. 
 
2.6.7 Small scale plasmid preparation (Miniprep) 
Small scale plasmid preparation, also known as miniprep, is a simple way to purify 
plasmid DNA (pDNA) from bacterial cells. This was important in order to purify the 
cloned plasmids from bacterial DNA.  
From each plate, 4 or 5 white colonies were selected. Each colony (clone) inoculated a 
culture of 5 ml selective LB (100 µg/ml ampicillin) in 15 ml Falcon tubes. The tubes 
were loosely capped for aeration and incubated overnight at 37°C with vigorous 
shaking. After a maximum of 16 hours, the cultures were centrifuged at 4°C using a 
Beckman J2-21 centrifuge (BeckmanCoulter) to pellet the cells and the supernatant 
discarded. A labelled replica plate was made with some cells from each culture, 
incubated overnight at 37°C to allow growth, and refrigerated to serve as a source of the 
original colonies. Plasmid DNA was then purified from the pelleted cells using the 
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2.6.8 Quantitative and qualitative analysis of plasmid DNA 
The pDNA obtained was quantified on a spectrophotometer and qualitatively analysed 
by agarose gel electrophoresis. A NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies) was used to determine the concentration and purity of the pDNA.  DNA 
concentration was measured in ng/µl and the protein/DNA ratio, which gives an 
indication of contaminating proteins and thus purity, was also recorded. Only samples 
with ratios between 1.8 and 2.0 were regarded as suitable for use in subsequent 
experiments. 
 
 Two microlitres of pDNA were then combined with 3 µl loading buffer, loaded on to a 
0.8% w/v agarose gel and electrophoresed in 1 x TBE buffer at 80V for approximately 
one hour. After electrophoresis, the DNA was visualised under UV light as previously 
described. Plasmid DNA has various forms, circular, nicked/linear and super coiled. 
Each form is electrophoresed through an agarose gel at different speeds, and can thus 




Figure 2.6 Gel photograph showing the different forms of plasmid DNA, circular, 
nicked/linear and super coiled. The DNA was electrophoresed on a 0.8% agarose gel stained 
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2.6.9 Restriction endonuclease digestion 
To confirm the presence of the U6/shRNA cassette in a selected clone, a RE digestion 
was performed using EcoRI (Promega) on the purified pDNA. The reaction was set up as 
follows: 200 ng of pDNA, 12 units EcoRI, 1 x Buffer H (Promega) made up to a final 
volume of 20 µl with sH2O. The reaction was incubated at 37°C for 2 hours. Ten 
microlitres of the digest product were then combined with 3 µl loading buffer, loaded 
onto a 0.8% w/v agarose gel and electrophoresed in 1 x TBE at 100V for 45 minutes. 
Two microlitres of the undigested pDNA were combined with 3 µl loading buffer and 
electrophoresed alongside the digested DNA for comparison. A size standard, 
GeneRuler™ 1kb DNA Ladder (Fermentas, appendix C) was included on the gel to 
enable estimation of the size of the insert. After electrophoresis, the DNA was 




Figure 2.7 Gel photograph showing digested and undigested plasmid DNA (shRNA 
cassettes). M = molecular weight marker, lanes 1 and 3 = undigested plasmid DNA,  
lanes 2 and 4 = digested plasmid DNA with the released insert indicated. Plasmid DNA was 
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2.6.10 Sequencing of plasmid/insert 
To confirm the sequence of the insert, DNA sequencing was performed as previously 
described. The cycle sequencing reaction (appendix C) was performed with 
approximately 500 ng pDNA from each clone and 24 pmol of the SP6 or the T7 primer 
(appendix A).  
 
2.6.11 Large scale plasmid preparation (Midiprep) 
Large scale plasmid preparation or midiprep, is a technique used to purify large 
quantities of pDNA from bacterial cultures. After a positive clone was selected and 
confirmed by RE digestion with EcoRI, and sequencing with SP6 or T7 primers, the 
corresponding colony was identified from the stored replica plate and 150 ml selective 
LB inoculated in a 250 ml conical glass flask. The flask was incubated overnight at 37°C 
with vigorous shaking and pDNA purified from the bacterial cells using the 
Midi/Maxiprep (QIAGEN,) according to the manufacturer‟s instructions. 
 
2.7 Plasmid construction/cloning (targets) 
Short target sequences of ATXN1 incorporating the target SNP, were cloned into the 
psiCheck 2.2 vector (Promega). The flow-diagram below outlines the steps performed for 
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The psiCheck 2.2 vector expresses both the Renilla and the Firefly luciferase reporter 








Figure 2.9 A schematic representation of the wild type (atx1-U-luc) and mutant (atx1-C-luc) 
dual luciferase reporter assay targets (adapted from Scholefield et al. 2009). The alleles 
indicated here are from the wild-type and mutant transcripts of ATXN1.  
SV40 – Simian virus 40, hRLuc – Renilla luciferase gene, hFLuc – Firefly luciferase gene,  
HSV TK – Herpes Simplex Thymidine Kinase 
 
2.7.1 Preparation of annealed dsDNA oligos 
The DNA oligonucleotides used for cloning the target plasmids were 62 nt long 
sequences incorporating the target SNP, and NotI and XhoI sticky ends (sequences in 
appendix A). The oligos were annealed and phosphorylated prior to ligation into 
psiCheck. Each oligo was phosphorylated in a separate reaction set up as follows: 100 
µM oligo, 10 mM ATP (Novagen), 5 units T4 polynucleotide kinase (PNK) (Novagen),  
1 x polynucleotide kinase buffer (Novagen), made up to 20 µl with sH2O. The reactions 
were incubated at 37°C for 1 hour. After phosphorylation, complementary oligos were 
mixed to a final concentration of 5 µM each, incubated at 75°C for 10 minutes to 
inactivate the enzyme, and then annealed by slow cooling (i.e. the heating block was 
switched off and allowed to cool). Aliquots of the annealed dsDNA oligos were diluted 
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2.7.2 Preparation of dephosphorylated psiCheck 2.2 vector 
In order to prepare the plasmid for ligation, a RE digestion was performed to give free 
ends, and dephosphorylated to minimise re-ligation.  
The RE digestion was set up as follows: 2 µg of psiCheck 2.2 vector, 10 units NotI 
(Promega), 15 units XhoI (Promega), 1 x compatible buffer D (Promega) and made up to 30 
µl with sH2O. The reaction was incubated at 37°C for 2 hours. Thereafter, the following 
were added: 5 units Antarctic phosphatase (New England Biolabs), 1 x Antarctic 
phosphatase buffer (New England Biolabs) and made up to 40 µl with sH2O. This mixture 
was incubated for a further 1 hour at 37°C, after which the phosphatase was inactivated 
by incubation at 65°C for 15 minutes. The total volume was then combined with 5 µl 
loading buffer, loaded onto a 0.8% agarose gel and electrophoresed in 1 x TBE at 80V 
for 1 hour. After electrophoresis, the high molecular weight band was visualised under 
UV light and quickly excised. DNA was purified from the gel block using the 




The annealed dsDNA oligos were then ligated into the psiCheck 2.2 vector downstream 
of the Renilla reporter gene. A ligation reaction was set up between each of the 
phosphorylated dsDNA oligos and the linearised dephosphorylated vector, in a 1:3 ratio 
(vector:oligo). The reactions were set up as follows:  60 nM of psiCheck vector, 180 nM 
of dsDNA oligo, 5 units T4 DNA ligase (Fermentas), 1 x T4 DNA ligase buffer 
(Fermentas) and made up to 10 µl with sH2O. A negative control reaction was also set up 
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2.7.4 Transformation 
One hundred microlitres of competent cells were combined with 5 µl from each ligation 
reaction and transformation performed as previously described. Nine hundred 
microlitres of LB were added to each tube and incubated. Thereafter, 100 µl of the 
expression mix were plated on selective agar plates and incubated at 37°C overnight. 
After overnight incubation, the control plate should have none or very few colonies in 
comparison to the plates with transformants. This is an indication of successful ligation. 
  
2.7.5 Small scale plasmid preparation (Miniprep) 
Each colony on the transformed plate was picked to inoculate selective LB and small 
scale purification carried out on the bacterial cultures as previously described.  
 
2.7.6 Quantitative and qualitative analysis of plasmid DNA 
The purified pDNA was analysed quantitatively and qualitatively as previously 
described. 
 
2.7.7 Restriction endonuclease digestion 
To confirm the presence of the cloned target, a RE digestion was performed using 
EcoRV (Roche). The reaction was set up as follows: 200 ng of pDNA, 10 units EcoRV, 1 
x buffer B, made up to a final volume of 20 µl with sH2O. The reaction was incubated at 
37°C for 2 hours. Digest products were then electrophoresed on a 0.8% w/v agarose 















Figure 2.10 Gel photograph showing digested and undigested plasmid DNA (targets).  
Lanes 1, 3 and 5 = undigested plasmid DNA. Lanes 2, 4 and 6 = digested plasmid DNA with 
the released insert as indicated. Plasmid DNA was electrophoresed on a 0.8% agarose gel 
stained with EtBr and visualised under UV light. 
 
 
2.7.8 Sequencing of plasmid/insert 
Sequencing was performed directly on the pDNA to confirm the sequence of the insert 
as previously described. The cycle sequencing reaction (appendix C) was set up with 
approximately 500 ng of each of the purified pDNA and 24 pmol of psi-F or psi-R 
primer (appendix A).  
 
2.7.9 Large scale plasmid preparation (Midiprep) 
After identification of a positive clone by RE digest with EcoRV and confirmation by 
sequencing with psi-F or psi-R primers, the corresponding colony was identified from 
the stored replica plate and large scale preparation carried out on the bacterial cultures 
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2.8 Cell-based assays 
2.8.1 Maintenance of cell lines 
All transfection experiments were performed in HEK293 cells. The HEK293 cell line is 
well-known and commonly used for in vitro experiments. Cells were cultured in 
Dulbeco‟s modified Eagle‟s medium (DMEM) (Sigma-Aldrich) supplemented with 10% 
v/v Fetal Calf serum (FCS) (Sigma-Aldrich), Penicillin-Streptomycin (Sigma-Aldrich) and 
Fungin (Invitrogen). The cells were maintained in a 37°C incubator with controlled 
carbon dioxide levels and medium replaced every three to four days. 
 
2.8.2 Transfections 
HEK293 cells were seeded in 24-well plates at approximately 120 000 cells per well. The 
plasmid transfections were performed using Lipofectamine2K (Invitrogen) according to 
manufacturer‟s instructions, with a total of 1 µg of DNA in a 5:1 ratio of effector: target 
in each well. A GFP-expressing plasmid (100 ng) was co-transfected with the target-
expressing plasmid to give an indication of transfection efficiency. After 24 hours, the 
cells were transfected with the shRNA-expressing plasmid. A dual luciferase assay was 
performed 48 hours after the initial transfection.  
 
2.8.3 Dual luciferase reporter assay 
Reporter systems are commonly used to study gene expression and may be applied to 
intracellular signalling, mRNA processing and many others. The term “dual reporter” 
refers to the simultaneous expression and measurement of two individual reporter 
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One of these is the “experimental” reporter whose activity is correlated with the effect 
of the experimental conditions, while the other is the “control” reporter which provides 
a baseline response. Normalising the experimental reporter activity to the control 
reporter activity minimises experimental variability allowing more reliable interpretation 
of the results. The Dual-Luciferase® Reporter (DLRTM) Assay System (Promega) 
measures the luciferase activities of firefly (Photinus pyralis) and Renilla (Renilla reniformis) 
from a single sample. The firefly luciferase reporter is measured first by adding 
Luciferase Assay Reagent II (LAR II). After quantifying the luminescence, this reaction 
is quenched and the Renilla reaction initiated by adding Stop and Glo® Reagent 
(www.promega.com). 
 
Forty-eight hours after transfection, cells were washed in 1 x phosphate buffered saline 
(PBS) (Sigma-Aldrich) and harvested by incubating with 1 x passive lysis buffer (PLB) 
(Promega) for fifteen minutes. Forty micro litres of each sample were pipetted into 
individual wells of a white luminometer microplate. Forty microlitres of LAR II was 
added to each well, the plate was loaded into a Veritas Microplate Luminometer (Turner 
Biosystems) and firefly luciferase activity measured. Thereafter, the Stop and Glo® 
Reagent was added to each well and the plate re-loaded into the luminometer to 
measure the Renilla luciferase activity. Readings were recorded on a computer connected 
to the luminometer. Renilla luciferase/firefly luciferase ratios were analysed in relation to 
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3. Results 
SECTION I: Construction of a SNP-based haplotype 
around the SCA1 locus  
3.1 SNP genotyping results 
3.1.1 Restriction endonuclease digestion 
Following PCR amplification, four of the five selected SNPs were genotyped by RE 
digestion. Figure 3.1 shows examples of the results obtained for each SNP. All samples 
analysed for SNP1 showed the same genotype (figure 3.1 (a)). This SNP was deemed to 
be non-informative and was not included in further analyses. This result will be 





























   
 
 
Figure 3.1 Gel photographs showing examples of SNP digest products.  
(a) SNP1 PCR products after digestion with AluI showing CC genotypes. (b) SNP3 PCR 
products after digestion with StuI showing AA, GG and AG genotypes. (c) SNP4 PCR 
products after digestion with AvaII (Eco47I) showing CC, TT and CT genotypes. (d) SNP5 PCR 
products after digestion with BslI showing CC, TT and CT genotypes. M = molecular weight 
marker. All digest products were electrophoresed through 2% agarose gels stained with 
EtBr and visualised under UV light. Gel photo in (b) is inverted for a clearer view of digest 
products. Note that the indicated alleles are from the reverse genomic DNA sequence as on 
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3.1.2 Single-strand conformational polymorphism 
Due to the absence of a suitable restriction site, SNP2 was genotyped by SSCP analysis. 
Figure 3.2 shows an example of the results obtained from SSCP, with the genotype 
patterns determined after sequencing. 
 
 
Figure 3.2 Gel photograph showing the SSCP banding patterns and respective genotypes for 
SNP2. The gel was stained with silver and photographed using a digital camera. Note that 
the indicated alleles are from the reverse genomic DNA sequence 
 
 
3.1.3 SNP allele frequencies 
Table 3.1 gives a breakdown and comparison of the allele frequencies for patients and 
controls. 
Table 3.1 SNP allele frequencies, Patients and Controls 
 SNP2 SNP3 SNP4† SNP5* 
T C T C G A G A 
Patients  (N = 54) 0.41 0.59 0.9 0.1 0.69 0.31 0.55 0.45 
Controls (N = 150) 0.37 0.63 0.67 0.33 0.39 0.61 0.67 0.33 
 
Key: 
           = skewed distribution, N = total number of genotyped alleles for each SNP 
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Note that the indicated alleles are from the forward strand. Importantly, SNP3 and 
SNP4 highlighted in the table above (green box), show a significantly skewed 
distribution of the T allele in the affected individuals when compared to the control 
population (p = 0.0003 and p = 0.0012, respectively). A p-value less than 0.05 is 
considered significant.  
 
3.2 Family studies 
Eight triads were initially selected from five of the six kindreds of mixed ancestry 
investigated in the previous study (Ramesar et al. 1997): CA1, CA2, CA4, CA8 and 
CA11. It was necessary to genotype additional family members in order to establish 
phase thus expanding the triad. Cyrillic software was used to draw the family pedigrees. 
A total of 41 individuals were genotyped for CAG repeat length (normal and expanded 
alleles), and for the selected SNPs. Twenty-seven subjects carried an expanded repeat 
and the rest had two normal alleles. Normal repeat sizes ranged from 26 to 32 repeats 
while the expanded repeat sizes ranged from 47 to 66 repeats. All genotyping results 
were entered into Cyrillic and segregation analysis used to construct SNP haplotypes for 
each individual. 
 
Pedigrees were drawn for the 5 families, figure 3.3 (a-e). Where a DNA sample was 
unavailable, genotypes were inferred if possible. The disease-associated haplotypes were 
highlighted as coloured bars. Note that the alleles indicated in the pedigrees are named 





























































































Figure 3.3 a) Pedigrees from Family 1. 
Haplotypes constructed with SNP genotypes obtained from this study. Blue bars represent 
the haplotype associated with the CAG expansion. Circles represent females, squares 






































































































Figure 3.3 b) Pedigrees from Family 2.  
Haplotypes constructed with SNP genotypes obtained from this study. Blue bars represent 
the haplotype associated with the CAG expansion. Circles represent females, squares 
represent males. Filled in symbols are affected individuals. Symbols with a “?” inside 
indicate unknown clinical status. A line through the symbol represents a deceased 

















































































Figure 3.3 c) Pedigree from Family 4.  
Haplotypes constructed with SNP genotypes obtained from this study. All loci are shown in 
5’ to 3’ orientation. Blue bars represent the haplotype associated with the CAG expansion. 
Circles represent females, squares represent males. Filled in symbols are affected 
individuals. A line through the symbol represents a deceased individual. Genotypes in 









































































Figure 3.3 d) Pedigree of Family 8.  
Haplotypes constructed with SNP genotypes obtained from this study. All loci are shown in 
5’ to 3’ orientation. Orange bars represent the haplotype associated with the CAG 
expansion. Circles represent females, squares represent males. Filled in symbols are 
affected individuals. A line through the symbol represents deceased individuals. Symbols 
with “?” inside indicate unknown clinical status. Genotypes in brackets “()” are inferred. “?” 




















































   

















































Figure 3.3 e) Pedigrees from Family 11.  
Haplotypes constructed with SNP genotypes obtained from this study. All loci are shown in 
5’ to 3’ orientation. Orange bars represent the haplotype associated with the CAG 
expansion. Loci with missing genotype data are represented by “?”. Circles represent 
females, squares represent males. Filled in symbols are affected individuals. Symbols with 
“?” inside indicate unknown clinical status. Genotypes in brackets “()” are inferred. “?” 
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It should be noted that for an autosomal dominant disorder such as SCA1, only half of 
the alleles investigated are associated with the disease-causing mutation. Table 3.2 below 
summarises the two disease-associated haplotypes. The colours in the table correspond 
to those of the haplotypes linked to the expansion in the pedigrees (figure 3.3). The blue 
colour highlights families 1, 2 and 4 associated with haplotype 1 (Hap1) while orange 
highlights families 8 and 11 associated with haplotype 2 (Hap2). Also highlighted is a 
minimum shared interval common across both haplotypes (red box). This interval 
encompasses SNPs 3 and 4 which are downstream of the CAG repeat, 5‟ to 3‟ 
orientation). The two SNPs were in the previous section found to be closely linked to 
the CAG expansion in both disease-associated haplotypes. 
 
Table 3.2 Mixed Ancestry family haplotypes associated with the SCA1 expansion. 
SNP FAMILY 
CA 1 CA 2 CA 4 CA 8 CA 11 
SNP2 
 
T T T C C 
 
Position of CAG repeat      
SNP3 
 
T T T T T 
SNP4 
 
G G G G G 
SNP5 
 
G G G A A 
 
Key: 
          = Minimum shared interval  
blue background = Hap1, orange background = Hap2 
 
Note that the haplotypes highlighted in the table were those constructed from the 
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3.3 Statistical analysis  
The SCA1 affected individuals (patients) in this section were all part of the family 
studies (Section 3.2). A total of 27 affected individuals and 75 unaffected unrelated 
controls were genotyped and analysed. The controls were analysed in order to establish 
HWE for the selected SNPs; and to test the occurrence of the disease-associated 
haplotypes in the background population using PHASE. 
 
3.3.1 Hardy-Weinberg equilibrium 
Genotyping data from 75 unrelated unaffected control subjects of Mixed Ancestry 
origin was used to establish which SNPs are in HWE in this population. This was done 
by performing an exact test (degree of freedom = 1) and assigning a corresponding p-
value (significance). A p-value less than 0.05 is indicative of a population that is out of 
HWE. All 4 SNPs were found to be in HWE with p-values greater than 0.1. 
 
3.3.2 PHASE analysis 
PHASE analysis was performed on the control cohort to test the occurrence of the 
disease-associated haplotypes in the background population. PHASE was also used on 
the affected individuals to test the frequency of the disease-associated haplotypes 
obtained by segregation analysis. In order to prevent bias, separate input files were 
created for 27 SCA1 affected individuals from the 5 Mixed Ancestry families, and for 75 
unaffected unrelated controls from the Mixed Ancestry sub-population. Analysis was 
performed on the two groups. The output files (frequencies) obtained from PHASE are 
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a)     index    haplotype  E(freq)      S.E 
         1        1101    0.080000    0.000000 
         2        1100    0.320000    0.000000 
         3        1001    0.080000    0.000000 
         4        1000    0.040000    0.000000 
         5        0101    0.200000    0.000000 
         6        0100    0.020000    0.000000 
         7        0111    0.060000    0.000000 
         8        0001    0.140000    0.000000 




index    haplotype   E(freq)      S.E 
         1        0000    0.029407    0.011278 
         2        0001    0.057340    0.016142 
         3        0010    0.004305    0.004983 
         4        0011    0.062160    0.014061 
         5        0100    0.072459    0.014579 
         6        0101    0.051153    0.015120 
         7        0110    0.013479    0.006011 
         8        0111    0.026581    0.010474 
         9        1000    0.151584    0.017961 
        10        1001    0.182046    0.020321 
        11        1010    0.043998    0.012696 
        12        1011    0.080525    0.017928 
        13        1100    0.041904    0.015776 
        14        1101    0.085288    0.016829 
        15        1110    0.024698    0.011524 
        16        1111    0.073074    0.015894   
  
Figure 3.4 Output files from PHASE analysis of Mixed Ancestry patients and controls.  
a) Output file from PHASE analysis of Mixed Ancestry patients. b) Output file from PHASE 
analysis of Mixed Ancestry controls. Nucleotides are represented by 0s and 1s (A/T = 0,  
G/C = 1). E(freq) is an estimate of the haplotype frequency of the sample. S.E is the 
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The estimated haplotype frequencies of each sample analysed can be used as estimates 
of the population haplotype frequencies. The two disease-associated haplotypes 
highlighted in red, 1100 and 0101 (figure 3.4), correspond to Hap1 and Hap2 
respectively (table 3.2) in the following order: SNP5-SNP4-SNP3-SNP2. As expected, 
results from PHASE show that the two haplotypes have significantly higher frequencies 
in the affected individuals Hap1 E(freq)=0.32 and Hap2 E(freq)=0.20, compared to the 
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SECTION II: Allele-specific silencing 
3.4 Selected SNP targets 
Subsequent to the genotyping of SNPs for the SNP-based haplotype, two SNPs were 
identified as possible targets for allele-specific silencing, with both showing fairly high 
heterozygosity. SNPs 2 and 4 were heterozygous in 62% and 55% respectively, of the 
patient population. However, it was determined that the mRNA sequence 
(NM_000332.3, NCBI) used as a reference in this study does not carry SNP2. Allele-
specific silencing was thus attempted using effectors targeting SNP4 for which the G 
allele is associated with the expansion in both haplotypes identified in the Mixed 
Ancestry SCA1 families. 
 
3.5 Plasmid construction/cloning 
3.5.1 shRNA cassettes 
Subsequent to successful PCR, the U6/shRNA cassettes were cloned into the pGEM-T 
Easy vector. Plasmid DNA was purified and positive clones selected by restriction 
enzyme digestion with EcoRI. DNA sequencing was performed to confirm the correct 
shRNA sequence for each construct. Large scale plasmid purification was then 
performed to yield sufficient pDNA for transfection into HEK293 cells. 
 
3.5.2 Targets 
The short ATXN1 target sequences were successfully cloned into the psiCheck 2.2 
vector, downstream of the Renilla reporter gene. Plasmid DNA was purified and positive 
clones selected by restriction enzyme digest with EcoRV. DNA sequencing was 
performed to confirm the correct target sequence. Large scale plasmid purification was 
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3.6 Transfection studies 
A GFP-expressing plasmid was co-transfected with the shRNA- and target-expressing 
plasmids. Twenty four hours after transfection, the cells were viewed under a 
fluorescent microscope and photographed. GFP expression gives an indication of 
efficiency (figure 3.5). Cells in figure 3.5 a) were approximately 80% confluent and 
clearly show a fairly high level of transfection.  
 
 
Figure 3.5 Representative images of transfected HEK293 cells viewed under a fluorescent 
microscope. a) Cells under green fluorescence (10X). b) Cluster of cells under brightfield 
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3.7 Results of a dual luciferase reporter assay 
Multiple shRNAs were designed to incorporate the mismatch created against the wild-
type transcript. The mismatch was placed successively in positions 9 to 16 from the  
5‟ end of the guide strand. Forty eight hours after transfection, a dual luciferase reporter 
assay was used to screen the shRNAs against short target sequences (62 nt) of either the 
wild-type or the mutant transcript. The results of this assay are displayed graphically in 
figure 3.6 below. 
 
Figure 3.6 A graph showing the results of a dual luciferase assay using a series of 
mismatched shRNAs targeting SNP4. The relative values of Renilla luciferase (hRLuc) 
expression are normalised to firefly luciferase (hFLuc) expression in each case. Each 
experiment was performed in triplicate. Data was averaged and normalised to the non-
specific (NS) control. Relative expression of wild-type (atx1-U-luc) and mutant (atx1-C-luc) 
targets is represented by purple and red bars respectively with error bars showing standard 
deviation. Statistically significant differences (p < 0.05) between wild-type and mutant 
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Other than shR-p12, all the constructs showed statistically significant discrimination 
between the wild-type and mutant (p < 0.05) as indicated in figure 3.6. Results from 
shR-p12 showed a p-value which is not statistically significant. This was due to an 
outlier value in the measured luciferase activity which creates a very large standard 
deviation. Results from the other constructs show a trend in discrimination with an 
increase from left to right of the figure i.e. the further away the mismatch is from the 
seed region. shR-p9, -p10 and -p11 show significant discrimination but also have fairly 
wide error bars. shR-p13 shows knockdown of the wild-type and the mutant to 
approximately 90% and 60% respectively. shR-p14 shows minimal knockdown of the 
wild-type to just under 100%, while the mutant is reduced to just below 40%. shR-p15 
shows very significant discrimination (p<0.001) with knockdown of wild-type and 
mutant at approximately 90% and 30% respectively. shR-p16 is the most effective 
construct with minimal knockdown of the wild-type to approximately 90% and the 
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4. Discussion 
4.1 Haplotype study 
Due to numerous large studies carried out only in first world countries, there is a gross 
under-representation of African genotypes on international databases such as NCBI. 
Examination of the region of interest for SNPs to be used in the construction of the 
SNP-based haplotype reinforced this. There is a severe lack of genotype information 
specifically for the sub-Saharan African populations, and several SNPs were disqualified 
due to the unavailability of minor allele frequencies and heterozygosity information. 
However, the HapMap (www.hapmap.org), 1000 Genomes (www.1000genomes.org) 
and the Africa Genome (www.africagenome.com) projects are attempting to address the 
issue of a lack of collated information by genotyping various African populations. 
  
4.1.1 Confirmation of reported haplotypes 
The first aim of the present study was to narrow the region investigated by Ramesar and 
colleagues (Ramesar et al. 1997) and to confirm the two founder effects by constructing 
a SNP-based haplotype. The SNP-based haplotype was successfully constructed using 
genotypes from four SNPs across a region spanning the ATXN1 gene.  
 
Figure 4.1 shows the positions of the ATXN1 gene, the SNPs used in this study and the 
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Figure 4.1 Diagram showing the ATXN1 gene, and the positions of the microsatellite 
markers (D6S260, D6S89 and D6S274) in yellow (Ramesar et al. 1997). 1, 2, 3, 4 and 5 
indicate the positions of the SNPs used in the construction of the haplotype in this study 
 
The previous study investigated a large genomic area (approximately 10 Mb), as shown 
by the positions of the microsatellite markers in figure 4.1. In this study, the region 
investigated was approximately 470 kb. By narrowing the region using SNPs, the 
haplotypes constructed in this study have confirmed the two founder effects in the 
SCA1 families of Mixed Ancestry origin in the Western Cape. Families 1, 2 and 4 share a 
common haplotype designated Haplotype1 (Hap1), and families 8 and 11 share a second 
common haplotype designated Haplotype2 (Hap2) (table 3.2). These results correspond 
with the haplotypes assigned to the families in the previous study. 
 
As mentioned briefly in chapter 3, SNP1 (rs471716) showed the same genotype (GG) 
for every individual. This SNP is located 5‟ to the microsatellite marker DS6S274 (in the 
direction of transcription) (figure 4.1). Further analysis of this region is required to 
ascertain the extent of the haplotype and breakpoints of the two haplotypes. This may 
be done by selecting and genotyping additional SNPs 5‟ to the marker D6S274 (i.e. 
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The results of such an analysis could provide more information related to the origins of 
the haplotypes in the Mixed Ancestry population.  
 
Table 3.2 summarises the haplotype information from the segregation analysis 
performed in this study. The table shows the existence of a minimum shared interval 
common across both haplotypes (red box). The interval encompasses SNPs 3 and 4 
(rs2075974 and rs180017 respectively), indicating that these two SNPs are in close 
linkage disequilibrium with the CAG expansion. This may suggest the possibility of a 
common origin for the two founder haplotypes, and thus the existence of a single 
original SCA1 haplotype in these Mixed Ancestry families.  
 
4.1.2 A different SNP haplotype identified in Family 8 
The SNP haplotypes constructed for individual CA8.6 in family 8 suggest the possibility 
of a recombination event on the normal allele. In figure 3.3 (d), the break-point in the 
haplotype is indicated by (    ). Due to the unavailability of DNA samples, parental 
genotypes were inferred from the haplotypes constructed for the children. A cross-over 
event occurring between the normal alleles of the father, in the region between SNPs 4 
and 5, may account for the different haplotype (C-T-A-G) in CA8.6.  
 
Alternatively, the haplotype may have a different paternal source. It is note-worthy that 
this haplotype (C-T-A-G) in individual CA8.6 corresponds to 1001 in the output file 
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index    haplotype   E(freq)      S.E 
         1        0000    0.029407    0.011278 
         2        0001    0.057340    0.016142 
         3        0010    0.004305    0.004983 
         4        0011    0.062160    0.014061 
         5        0100    0.072459    0.014579 
         6        0101    0.051153    0.015120 
         7        0110    0.013479    0.006011 
         8        0111    0.026581    0.010474 
         9        1000    0.151584    0.017961 
        10        1001    0.182046    0.020321 
        11        1010    0.043998    0.012696 
        12        1011    0.080525    0.017928 
        13        1100    0.041904    0.015776 
        14        1101    0.085288    0.016829 
        15        1110    0.024698    0.011524 
        16        1111    0.073074    0.015894   
 
Figure 4.2 PHASE output (controls). Disease-associated haplotypes are highlighted in red, 
the different haplotype from Family 8 is highlighted in green. 
 
The E(freq) for 1001 is 0.18 in the background population. This is the highest value for 
the SNP haplotypes constructed randomly by PHASE. The fact that this is the most 
common haplotype in the background population thus lends support that the paternal 
haplotype of individual CA 8.6 may have an alternative source. Unfortunately, due to 
the lack of DNA from the parents, there is currently no way of ascertaining which of 
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4.1.3 SCA1 founder effects in the Mixed Ancestry families 
The existence of a founder effect is not unusual in South Africa and has been previously 
reported for various genetic conditions such as keratolytic winter erythema (KWE) 
(Starfield et al. 1997), hypertrophic cardiomyopathy (HCM) (Moolman-Smook et al. 
1999), SCA7 (Greenberg et al. 2006) and HD (Scholefield and Greenberg 2007). A 
founder effect may be described as the loss of genetic variation. This usually occurs 
when a small group of individuals with origins in a larger group, establishes a new 
population in which the frequency of certain genetic variations and mutations increases 
due to limitations in the gene pool.  
 
The South African population is made up of groups of varying ethnic origin as a result 
of its location and colonisation history (de Wit et al. 2010). The main sub-populations 
are the Black African, Caucasian and Mixed Ancestry. The Mixed Ancestry population 
makes up just over 50% of the population of the Western Cape and is characterised by 
admixture of different populations. Recent genetic studies have supported historical 
data, showing the main components of the Mixed Ancestry population to be  the 
indigenous African people (the Khoesan and Bantu-speaking Africans), Europeans and 
peoples from Malaysia, Indonesia and the Indian subcontinent (Moolman-Smook et al. 
1999, Quintana-Murci et al. 2010, de Wit et al. 2010).  
 
A study performed in India reported the existence of a SCA1 haplotype in that 
population and linked rs2075974 (SNP3 in this study), to large normal (LN) alleles and 
expanded alleles (Mittal et al. 2005). The authors reported the T allele of this SNP linked 
to CAG repeats with two CAT interruptions. As discussed in chapter 1, these 
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The present study identified the T allele of this SNP in linkage disequilibrium with the 
expansion in SCA1 affected individuals, but made no assessment of interruptions. The 
South African population includes people of Indian origin and it may be relevant that 
the same SNP is linked to the expansion in both populations. Extending the haplotype 
constructed here to include the other SNPs used in the study of the Indian population 
may yield information with regard to this. It may also be useful to investigate the 
occurrence of CAT interruptions in a SCA1 cohort. Analysis of the CAT interruptions 
is performed by restriction enzyme digestion using SfaNI (Zühlke et al. 2002). This 
information may then be extrapolated to the diagnostic service offered by the Human 
Genetics Division, UCT. 
 
An attempt was also made to extend the haplotype to other ethnic groups by genotyping 
other SCA1 affected individuals. It was hoped that computational analysis following the 
genotyping, might be used to determine the origin of the SCA1 mutation. Unfortunately 
it proved to be impossible to perform this analysis essentially due to a lack of 
information in patient records, specifically on ethnicity. South Africa has had a difficult 
history with discrimination based on race. It is still a sensitive issue today and studies 
such as this are hindered by the lack of information that results from the perceived 
discriminatory nature of questions pertaining to race and ethnic background. However, 
it is now better understood that this information is relevant to genetic studies. 
Extending the haplotype to other ethnic groups may become possible as more patients 
and families are added to the Human Genetics Division database, which may provide 
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The occurrence of common haplotypes in the SCA1 patients (at least of Mixed 
Ancestry) in South Africa, suggests that the form of therapy investigated here may well 
be worth exploring further as it would benefit a larger percentage of patients than in 
populations where there is no common disease-associated haplotype. 
 
4.2 Allele-specific silencing 
Silencing of dominant genes has been shown to be useful in the development of therapy 
for various diseases such as ALS (Ding et al. 2003), HD (Harper et al. 2005) and SCA3 
(Miller et al. 2003). Although a SCA1 knock-out mouse model shows only a mild 
phenotype, allele-specific silencing is preferable for SCA1 in light of the fact that the 
exact function of wild-type ataxin-1 is unknown and its absence has been shown to have 
some neurobehavioral effects (Matilla et al. 1998, Xia et al. 2004).  
 
The second aim of this study was to identify any appropriate single nucleotide 
differences between wild-type and mutant SCA1 gene transcripts that may be exploited 
for allele-specific RNAi as has been done previously for SCA3 (Miller et al. 2003, Alves 
et al. 2008), and more recently for HD (Zhang et al. 2009) and SCA7 (Scholefield et al. 
2009). The results of this current study show that SNP4 (rs180017) may be successfully 
targeted to achieve allele-specific silencing for short target sequences of the SCA1 
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4.2.1 Target selection 
The attempt at allele-specific silencing followed on Section I of this study in which a 
SNP-based haplotype was constructed. Subsequent to genotyping of the SNPs selected 
for construction of the haplotype, two SNPs were identified in as possible targets for 
allele-specific silencing of the SCA1 gene. The two SNPs, SNP2 (in the 5‟ UTR) and 
SNP4 (in the 3‟ UTR) were found to be heterozygous in 62% and 55% respectively of 
the affected individuals genotyped in this study. This level of heterozygosity initially 
suggested that successful targeting of either or both of these polymorphisms would 
make a significant difference to this patient population. 
 
Two online databases (Ensembl and NCBI) were used to select SNPs and obtain 
information on their genomic positions, heterozygosity and MAF. To investigate 
silencing of the mutant transcript, it was then necessary to identify the mRNA 
transcripts of the ATXN1 gene to determine the positions of the two SNPs considered 
as targets. As of November 2008, the Ensembl database had 2 different transcripts of 
the ATXN1 gene, one with 11 exons with both proposed target SNPs, and the other 
with 9 exons. The NCBI database had 2 variants of the same transcript (1 and 2), 
neither of which had SNP2. Subsequent to comparison of these transcripts and 
consultations with the database managers, it was determined that due to alternative 
splicing in intron 7 SNP2 was absent from the coding region of the gene. It was thus 
decided that variant 1 from NCBI (NM_000332.3) would be used as the reference 
sequence for this study. Ensembl database managers consequently retracted the 
transcript with 11 exons that included SNP2 in the coding sequence, and as of 
December 2009 published a single transcript with 9 exons. Therefore, SNP4 (rs180017), 
for which the G allele was found to be linked to the disease-causing expansion in over 
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Effectors were designed to target this SNP in order to test the feasibility of allele-
specific silencing of the mutant transcript in this cohort of SCA1 patients. Figure 4.3 




Figure 4.3 Allele-specific silencing may be achieved by targeting a heterozygous SNP.  
a) An effector sequence perfectly complementary (G:C) to the mutant transcript leads to its 
cleavage. b) The same effector sequence with incomplete complementarity (G:U) to the 
wild-type transcript does not lead to cleavage and allows expression of the wild type 
protein. 
 
The G allele (forward genomic sequence) linked to the expansion, is transcribed to a C 
in the mRNA sequence. Therefore effectors were designed incorporating a G in this 
position to complement the mutant transcript and introduce a mismatch to the wild-
type transcript (figure 4.3). The wild-type genomic allele is an A which is transcribed to a 
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The mismatch introduced between the effector sequences and the mRNA transcript is a 
G:U, commonly referred to as a G:U wobble. This is a weak mismatch due to the 
formation of a single hydrogen bond between the purine G and pyrimidine U (Schwarz 
et al. 2006).  
 
4.2.2 Mismatch placement 
Several factors must be taken into consideration when attempting allele-specific 
silencing; the strength of the mismatch, its position within the guide sequence and 
whether or not the target sequence is amenable for RNAi. The type (and therefore 
strength) of the mismatch and accessibility of the target cannot be controlled since these 
depend on the SNP itself. The placement of the mismatch however can be varied and 
this has been shown in several studies (Miller et al. 2003, Ding et al. 2003, Li et al. 2004, 
Schwarz et al. 2006).  
 
It was previously believed that placing the mismatch between position 10 and 11 (with 
position 1 being the first nt of the 5‟ end of the guide strand), would achieve the greatest 
discrimination by impairing cleavage of target mRNA at its natural site and thus 
minimising knock-down of the wild-type allele (Leuschner et al. 2006). However, an 
extensive study performed by Schwarz and colleagues in 2006, reported that mismatches 
3‟ to the seed region promoted single nucleotide discrimination. Short interfering RNAs 
with the mismatch in positions 10 and in particular 16 consistently showed high levels 
of discrimination (Schwarz et al. 2006). A similar result was obtained by Scholefield et al. 
targeting the atxn7 mutant transcript (Scholefield et al. 2009) with full-length assays 
showing the mismatch in position 16 achieving the greatest selectivity. Thus for this 
study, a set of eight effector sequences were designed with the mismatch placed from 
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4.2.3 Dual luciferase reporter assay 
A dual luciferase reporter assay was used to investigate the feasibility of targeting the 
particular SNP in this sequence as well as the placement of the mismatch. The results of 
the luciferase assay (figure 3.6) demonstrate that despite using a fairly weak mismatch to 
the wild-type allele (figure 4.3), there is significant discrimination shown at almost every 
position. Positions 14, 15 and 16 show a particularly high level of discrimination. Using 
tiled siRNAs Schwarz and colleagues reported that little or no discrimination was 
achieved by mismatches other than of purine:purine siRNA:target RNA pairing 
(Schwarz et al. 2006). Our findings are in contrast to this, with fairly substantial 
discrimination being achieved by a purine: pyrimidine mismatch.  
 
To our knowledge, this is the first study that investigates allele-specific silencing for 
SCA1 and only the second study to successfully show discrimination between alleles 
based on a weak mismatch. As such, this work supports the development of allele-
specific silencing for SCA1 patients in South Africa. It also supports the use of this 
approach for other disorders and conditions with discrimination based on weak 
mismatches. The findings of this study are also in line with the results reported by 
Schwarz et al. and Scholefield et al., with the mismatch at position 16 in the hairpin 
achieving the highest level of discrimination in this system (Schwarz et al. 2006, 
Scholefield et al. 2009). In light of the positive results described here, there is much 
more to be done to investigate the development of allele-specific silencing for the SCA1 
gene. Some suggestions are outlined in the next section addressing future work. Any 
information derived from the development of this technique as a form of therapy may 
well be applied to other population groups around the world to alleviate disease 











Page | 98  
 
5. Future prospects and conclusion 
5.1 SCA1 haplotypes 
Further analysis is required with regard to the SNP-haplotypes constructed. 
Unfortunately, this study was unable to determine the extent of the haplotypes and 
therefore the origins. To this end, extending the SNP-based haplotype to SCA1 
individuals from other ethnic groups in South Africa may provide additional 
information. 
 
As mentioned, an investigation into the occurrence of CAT interruptions in SCA1 
affected individuals may also provide some information relevant to the origin of the 
founder haplotypes identified. In spite of the fact that CAT interruptions have been 
reported to stabilise the CAG repeat, this analysis is not offered as part of the molecular 
diagnostic service in the Human Genetic Division at UCT. A study into the frequency 
of interruptions in these SCA1 individuals/families may add significance to diagnostic 
results. Individuals carrying a CAG repeat with a stabilising interruption are unlikely to 
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5.2 Development of an RNAi-based therapy for SCA1 in South Africa 
5.2.1 Cellular models 
Given the success realized by targeting this sequence, future work should focus on 
whether these results can be replicated in a system that more closely mimics the SCA1 
disease state such as in a neuronal cell line or a SCA1 mouse model. As investigated 
here, using short targets around the selected SNP does not give complete information 
with regard to the knock down of the target mRNA.  
 
It has been reported that the secondary structure of full-length mRNA can affect the 
efficiency of cleavage by RISC (Shao et al. 2007). The silencing of SCA7 investigated by 
Scholefield et al. supported this, with knock down efficiency of full-length targets lower 
than that achieved in a luciferase assay (Scholefield et al. 2009), and the most 
discriminating  effector having the mismatch in different positions in the two systems. 
The shRNAs designed in this study thus need to be screened against full-length 
ATXN1 transcripts fused to reporter genes in a heterozygous cellular system. In the 
heterozygous system the mutant and wild-type targets are co-transfected, giving a closer 
approximation of the in vivo state since both mutant and wild-type transcripts exist 
together within the patient cells. 
 
This study and many others use human embryonic kidney (HEK) cells due to their 
amenability for cell culture and transfection; however they are generally not considered 
an ideal model. The inability to sample live brain cells severely limits knowledge of 
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A closer cellular model for a neurodegenerative disease such as SCA1 would thus be 
beneficial. In spite of the wide-spread expression of ataxin-1 protein, disease pathology 
is only evident in a small subset of neuronal cells and the reason for this selectivity is not 
yet understood. Recently, advances have been made to enable a study that gives a more 
ideal model of disease using induced pluripotent stem (iPS) cells (Chamberlain et al. 
2008, Marchetto et al. 2010).  
 
Human iPS cells are defined as having the potential to give rise to many, or all human 
tissue types. The cells can be generated by introducing reprogramming factors using 
retroviral vectors. These factors have the ability to reverse a differentiated cell to a 
pluripotent state, such that the cell can then be driven to form a different cell type. This 
technique thus offers the opportunity to model specific disease from available patient 
fibroblasts (Chamberlain et al. 2008, Vierbuchen et al. 2010, Marchetto et al. 2010). Ebert 
and colleagues reported the generation of iPS cells from skin fibroblasts taken from a 
patient with spinal muscular atrophy (SMA), the first study to show that human iPS cells 
can be used to model the specific pathology seen in an inherited disease (Ebert et al. 
2009). Several other studies have also examined the reprogramming of fibroblasts for 
human neurological diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson 
disease (PD) with some success (Marchetto et al. 2010). There is much work to be done 
yet, but iPS cells present enormous potential both as models of disease as well as for 
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5.2.2 Modification of effectors  
Experiments using these guide sequences in pri-miRNA would be a positive step 
towards the development of an RNAi-based therapy for South African SCA1 patients 
specifically, as well as other populations around the world. In comparison with the 
shRNA molecules used in this study, pri-miRNAs follow a more natural pathway since 
they closely resemble the endogenous RNAi substrates (Boudreau et al. 2008, Weinberg 
and Wood 2009). They also have the advantage of tissue-controlled expression, whereas 
the shRNA expression off Pol II or Pol III promoters for the most part cannot be 
tightly regulated which may have undesirable effects on the RNA processing pathway.  
As mentioned in chapter 1 (section 1.5), the development of a miRNA expression 
system may circumvent the issues of neurotoxicity as reported in a knockin HD mouse 
model (McBride et al. 2008). 
 
In 2008, Ohnishi and colleagues reported improved discrimination between wild-type 
and mutant alleles by the introduction of base substitutions in the guide strand of 
siRNAs and shRNAs (Ohnishi et al. 2008). The resulting sequences are predicted to 
have one mismatch against the mutant and two against the wild-type allele. The authors 
speculate that the disruption of base-pairing in the seed region as well as the centre of 
the guide strand reduces recognition and/or silencing against the wild-type alleles 
possibly due to the thermodynamics involved (Ohnishi et al. 2008). However, 
supplementary data from the study by Scholefield and colleagues suggests that the use 
of a double mismatch to the wild-type does not significantly improve discrimination 
(Scholefield et al. 2009). It may still be worthwhile to examine the effect of such 
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A major issue that must yet be addressed is delivery to the CNS. As outlined in chapter 
1, there are various hurdles to delivering RNAi effector molecules to the brain. Several 
studies have had success with various modifications of the molecules as well as delivery 
of expression vectors (Singh and Hajeri 2009), and investigation is on-going into safe 
and specific delivery of RNAi effectors. 
 
5.2.3 Animal models 
RNAi as a therapeutic technique has already been tested in a SCA1 transgenic mouse 
model with promising results (Xia et al. 2004). Xia and colleagues used recombinant 
AAV vectors expressing shRNAs flanking the CAG repeat region. The vectors were 
injected into the cerebellums of the SCA1 mice and results showed a marked 
improvement in cellular and behavioural characteristics. A similar model needs to be 
used to test the efficacy as well as required dosage of the effectors and at what stage the 
therapy should be applied. Another study on a conditional SCA1 mouse model suggests 
that early removal of the mutant protein is beneficial (Zu et al. 2004). 
 
Various investigations into animal models also suggest that allele-specific RNAi may not 
be essential for SCA1 therapy. Ataxin-1 knockout mice show only mild neurobehavioral 
characteristics (Matilla et al. 1998). Thus, it may not be necessary to achieve complete 
selectivity between mutant and wild-type alleles in order to offer an RNAi therapeutic. 
If the mutant allele is knocked down to a large extent, then it is possible that a fairly low 
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This kind of non allele-specific silencing has recently been investigated in rodent models 
for HD (Drouet et al. 2009, Boudreau et al. 2009). Lentiviral vectors were developed to 
allow the regulated expression of shRNAs targeting either wild-type or mutant alleles. 
Results suggest that local inactivation of endogenous huntingtin in brains of adult mice 
is feasible and has no serious consequences, at least over several months. Residual 
protein levels appear to be sufficient for biological functioning.  
 
Another study has taken a similar approach for SCA3. Alves et al. used LV vectors to 
either over-express wild-type human ataxin-3 or silence endogenous ataxin-3 in a rat 
model of SCA3 (Alves et al. 2010). Results indicated the absence of a role for ataxin-3 
and led them to investigate the silencing of both mutant and wild-type ataxin-3. Non-
allele-specific silencing led to robust reduction of neurodegeneration (Alves et al. 2010). 
For both HD and SCA3 global silencing appears to offer the chance to treat all patients 
with one product. This kind of approach may be well-worth investigating in the 
development of a therapy for SCA1 but for any of these diseases safety and efficacy 
need to be extensively studied in different disease models. Alternatively, global 
knockdown of the mutant and wild-type transcripts and simultaneous replacement of 
the wild-type with an RNAi- resistant transgene may be possible (Scholefield and Wood 
2010). The choice of which approach to employ is largely dependent on how tolerable 
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5.3 Conclusion 
In conclusion, further analysis is required with regard to the SCA1 founder haplotype in 
the South African Mixed Ancestry population. Extension of the haplotype to include 
other SNPs and investigation of patients from other ethnic groups may resolve the issue 
of the extent of the founder haplotype as well as its origins. 
 
With regard to the attempt to target SNP4 (rs180017) for allele-specific silencing of the 
SCA1 gene, the positive results recorded here suggest that it may be possible to develop 
an RNAi-based therapy for the sub-set of South African patients investigated, and 





























SCA1 PCR F  5’ gcggtcccaaaagggtcagt AAC TGG AAA TGT GGA CGT AC 3’ 
 
*R  5’ ggtcccaaaagggtcagt CAA CAT GGG CAG TCT GAG 3’ 
 
primers obtained from the molecular diagnostic laboratory, Human Genetics Division 








U6+1 universal F primer: 
 
5’ GATCGCAGATCTGGATCCAAGGTCGGGCAGGAAGAGGGCCT 3’ 
 
Long reverse oligos: 
 
P9    5’AAAAAGTGGGAAGGGCCCTGCAGGTGGGTCAGGCCCACAGGGCCCTTCCCACCGGTGTTTCGTCCTTTCCACAA 3’ 
P10  5’AAAAATGGGAAGGGCCCTGCAGGGTGGGTCAGGCCCCACAGGGCCCTTCCCACGGTGTTTCGTCCTTTCCACAA 3’ 
 
P11  5’AAAAAGGGAAGGGCCCTGCAGGGGTGGGTCAGGCCCCCACAGGGCCCTTCCCCGGTGTTTCGTCCTTTCCACAA 3’ 
 
P12  5’AAAAAGGAAGGGCCCTGCAGGGGTTGGGTCAGGACCCCCACAGGGCCCTTCCCGGTGTTTCGTCCTTTCCACAA 3’ 
 
P13  5’AAAAAGAAGGGCCCTGCAGGGGTGTGGGTCAGGCACCCCCACAGGGCCCTTCCGGTGTTTCGTCCTTTCCACAA 3’ 
 
P14  5’AAAAAAAGGGCCCTGCAGGGGTGCTGGGTCAGGACACCCCCACAGGGCCCTTCGGTGTTTCGTCCTTTCCACAA 3’ 
 
P15  5’AAAAAAGGGCCCTGCAGGGGTGCATGGGTCAGGCACACCCCCACAGGGCCCTCGGTGTTTCGTCCTTTCCACAA 3’ 
 





SP6 primer: 5’ ATTTAGGTGACACTATAGAA 3’ 
 





Psi-F: 5’ GACGCTCCAGATGAAATGGG 3’ 
 
Psi-R: 5’ GTGCCCGTGGCCACCAAGAC 3’ 
 
 
*SCA1 R is tagged with 6-FAM, a fluorescent label.
 
Long R oligos were obtained from Integrated DNA Technologies (Whitehead Scientific). 
The U6+1 universal F primer was provided by J. Scholefield.  
SP6 and T7 primers were available in the Human Genetics Division, UCT. 
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5’ TTGTGGAAAGGACGAAACACCG GTGGGAAGGGCCCTGTGGG CCTGACCCA CTGCAGGGCCCTTCCCACTTTTT 3’ 




























5’TTGTGGAAAGGACGAAACACCG GGGCCCTGTGGGGGTGTGG CCTGACCCA CTGCACCCCTGCAGGGCCCTTTTT 3’ 
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DNA oligonucleotides used for cloning of target plasmids (62 nt) 
 

















Pink – XhoI recognition site, Purple – EcoRV recognition site, Green – NotI 
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Appendix B: General recipes 
Tris Borate-EDTA (TBE) buffer 10X 
 108 g tris (hydroxymethyl) aminomethane 
 55 g boric acid 
 7.4 g ethylenediaminetetra-acetic acid (EDTA) 
Dissolve and make up to a final volume of 1 litre with distilled water. Dilute as required. 
 
Low electro-endosmosis (LE) agarose gels (w/v) 
0.8%: 0.4 g LE agarose in a final volume of 50 ml 1X TBE buffer with 3 µl EtBr  
(10 mg/ml) 
1%: 0.5 g LE agarose in a final volume of 50 ml 1X TBE buffer with 3 µl EtBr  
(10 mg/ml) 
2%: 1 g LE agarose in a final volume of 50 ml 1X TBE buffer with 3 µl EtBr  
(10 mg/ml) 
 
Agarose gel loading buffer 
 0.25% w/v bromophenol blue (0.125g) 
 40% w/v sucrose (20g) 
Dissolve and make up to a final volume of 50 ml with water. 
 
Single Stranded Conformational Polymorphism (SSCP) loading buffer (50 ml) 
 47.5 ml formamide (95%, v/v) 
 0.16 g 100 mM sodium hydroxide 
 0.125 g bromophenol blue 
 0.125 g xylene cyanol 
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Tris Borate buffer  1X 
 125.9 g tris 
 17.3 g boric acid 
 50 µl bromophenol blue (4% w/v) 
Dissolve solids and make up to a final volume of 1 litre with distilled water. Add 
bromophenol blue. 
 
Tris-formate buffer (0.75M) 
 90 g tris 
 Formic acid 
Dissolve tris in 200 ml distilled water; adjust pH to 9.0 with formic acid and make up to 
a final volume of 1 litre. 
 
40% acrylamide-PDA solution (w/v) 
 396 g acrylamide 
 4 g Piperazine diacrylamide (PDA) 
Dissolve and make up to a final volume of 1 litre with distilled water. 
 
12% non-denaturing polyacrylamide gel (v/v) 
 5.3 ml 40% (w/v) acrylamide-PDA solution 
 8.5 ml tris-formate buffer 
 3 ml 41% (v/v) glycerol 
 200 µl  10% (w/v) Ammonium Persulphate (APS) 
 20 µl TEMED 
 
Silver staining solutions (w/v) 
I. 0.1% silver nitrate solution 
Dissolve solid and make up to 1 litre with distilled water. 
II. Formaldehyde and sodium hydroxide solution 
 15 g sodium hydroxide pellets 
 20 ml 15% formaldehyde 
Dissolve pellets first in 200 ml distilled water, add formaldehyde and make up to a final 
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Luria broth (LB) 
 5 g Tryptone  
 2.5 g yeast extract 
 5 g sodium chloride 
Weigh into a clean bottle. Add 500 ml distilled water and autoclave.  
 
Selective agar plates 
 500 ml LB 
 7.5 g bacteriological agar 
 1 mg Ampicillin antibiotic dissolved in 1 ml sH2O 
Add agar to LB, autoclave and allow to cool. Once cool, add ampicillin to a final 
concentration of 100 µg/ml. Pour approximately 25-30 ml of agar into sterile plates (100 
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Appendix C: General protocols 
Standard PCR protocol 
A standard PCR experiment was performed in 0.2 ml tubes (Merck) as follows: 
Table showing set up of a standard PCR 
Reagent Final concentration 
Primers (F and R) 10 pmols 
dNTPs (Bioline) 0.2 mM 
GoTaq Reaction Buffer (Promega) 1X 
GoTaq DNA Polymerase (Promega) 1 U 
 
To each tube was added approximately 100 ng of genomic DNA and the final volume 
made up to 25 µl with sH2O (Adcock Ingram). Thermal cycling conditions were as 
follows: 1 cycle of initial DNA denaturation at 95°C for 3 min; 25 cycles of 
(denaturation at 95°C for 30s, annealing Ta for 30s, elongation at 72°C for 40s); 1 cycle 
of final elongation at 72°C for 10 min. Each experiment included a negative control 
(containing no DNA) to test for possible contamination of reagents.  
 
Cycle sequencing reaction 
A standard cycle sequencing reaction was performed follows: 
Table showing set up of cycle sequencing reaction 
Reagent Final concentration 
Primers (F or R) 10 pmols 
BigDye Terminator Mix (Applied Biosystems) 2 µl 
BigDye Sequencing Buffer (Applied Biosystems) 1X 
 
Each reaction contained 5-7 µl of extracted DNA or PCR product and was made up to 
a final volume of 20 µl with sH2O. Thermal conditions were as follows: 1 cycle of initial 
DNA denaturation at 96°C for 5 min; 25 cycles of (96°C for 30s, 50°C for 15s, 60°C for 
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Ethanol precipitation protocol 
1. Transfer cycle sequencing reaction product to a 1.5 ml eppendorf tube. 
2. Add 50 µl chilled absolute ethanol and 2 µl chilled sodium acetate  
(appendix B). 
3. Mix by vortexing and leave at -20°C overnight. 
4. Centrifuge at 10000 g for 10 minutes and discard the supernatant. 
5. Add 50 µl chilled 70% ethanol and mix by vortexing, repeat step 4 above. 
6. Leave tube uncapped and allow to air-dry for one hour. 
7. Re-suspend in 10 µl HiDi formamide (Applied Biosystems). 
 
QIAquick® gel extraction kit protocol 
1. Quickly and carefully excise DNA band from agarose gel using a clean sharp 
scalpel to minimise the amount of gel. 
2. Transfer gel slice to a clean 1.5 ml eppendorf tube and weigh. 
3. Add 3 volumes buffer QG to 1 volume agarose gel (100 mg ~ 100 µl). 
4. Incubate tube at 50°C for 10 minutes (or until gel slice is completely 
melted), vortex every 2 minutes. 
5. Add 1 volume isopropanol to 1 volume agarose gel and vortex. 
6. Place a QIAquick spin column into the provided collection tube. 
7. Apply the sample to the column and centrifuge to bind DNA. 
8. Discard flow-through and replace column in the collection tube. 
9. Add 0.75 ml buffer PE to the column and allow incubation at room 
temperature for 5 minutes. Centrifuge. 
10. Discard flow-through and centrifuge again. 
11. Place the column into a clean 1.5 ml tube and incubate at 37° for 5 minutes 
12. Add 30 µl de-ionised water to the column and allow incubation at room 
temperature for 2 minutes. 
13. Centrifuge to elute DNA. 
All centrifuging steps in the gel extraction protocol are carried out at 13000 rpm for 1 
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pGEM-T Easy vector ligation reaction 
Table showing set up of pGEM-T Easy ligation 
 Reaction (µl) Positive control (µl) Background control (µl) 
2X Rapid ligation buffer 5 5 5 
pGEM-T Easy vector 1 1 1 
PCR product X - - 
Control insert DNA - 2 - 
T4 DNA ligase 1 1 1 
sH2O  - 1 3 
 
All tubes were made up to 10 µl with sH2O. The reaction tube contained X µl (i.e. up to a 
maximum of 3 µl) of PCR product. The positive control tube contained control insert DNA 
provided in the pGEM-T Easy Cloning kit. The background control tube contained no DNA to 
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Gene ruler™ 100bp Plus DNA Ladder (Fermentas) 




GeneRuler™ 1kb DNA Ladder (Fermentas) 
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Division of Human Genetics Blood should be drawn in 2 plastic EDTA Tubes 
IIDMM, LEVEL 3 (Purple top) +/- 10ml each using a yellow barrel. 
UCT Medical School, Observatory 7925 Each tube should be inverted to mix and should be  
 clearly labelled with the patient's name and DOB 
Tel: (021) 406 6425        Fax: (021) 406 6826 Keep blood in fridge at 4°C until able to send to laboratory 
  
 Please DO NOT send specimens on ice or frozen. 
Please fill in all the information requested:  
 
Surname:____________________________________________ First Name(s):_________________________________________ 
 
New Family:  Yes    No    (If no, please fill in family name)  Family name: ________________________________________ 
 
Medical Aid: ________________________________________________Medical Aid No: ________________________________ 
 
Sex:     M        F    Date of Birth:  Year:_____________  Month:_____________________  Day: ______________________ 
 
Number  of children: ______________________________________ 
 
Ethnic Origin : ( please indicate ancestry of both your mother and father )_______________________________________________ 
        Fax: 
Contact Address:  ____________________________________ Town: _______________________ Tel: ___________________ 
 
        Fax: 
Referring Doctor/Sister: ______________________________ Town:  ______________________ Tel: ___________________ 
 
        Fax: 
Hospital or Address:  _________________________________ Town:  ______________________ Tel: ___________________ 
 
 
Reason for Referral  (Clinical diagnosis): 
 
Affected                At Risk                 Carrier                 Spouse                 Query                 Unaffected   
 
Becker Muscular Dys.  Duchenne Muscular Dys   Colonic Carcinoma   
Fragile-X Syndrome   Bipolar Disorder  Huntington Disease  
Retinitis Pigmentosa   Spinocerebellar Ataxia   Waardenberg Syndrome   
 
Additional disorders (apparent or previously treated):  ______________________________________________________________ 
 




Physical disability           Mental disability            Deafness             Impaired vision            Night blindness       
 
Other:  _________________________________________________________________________________________________ 
 
Have samples from this patient been sent to a DNA lab before? (DELETE WHERE NOT APPLICABLE)  YES / NO / Don't Know 
 
If Yes, where: ___________________________________________________________________________________________ 
 
For Laboratory use only: 
 
DNA number: _____________________________________   Vol. Blood: ________________(ml)     Other: _________________ 
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I, ____________________________________________________________________  , request that an attempt 
be made using genetic material to assess the probability that:  I /  my child  /  my  unborn child  (DELETE 
WHERE NOT APPLICABLE) might have inherited a disease-causing mutation in the gene 
for:______________________________________________________________________________________ 
  
2. I understand that the genetic material for analysis is to be obtained from:  blood cells/skin sample/other (specify) 
(DELETE WHERE NOT APPLICABLE) :     
  
3. I request that no portion of the sample be stored for later use.   (MARK IF APPLICABLE ) 
  Or 
I request that a portion of the sample be stored indefinitely for (DELETE WHERE NOT APPLICABLE): 
 ( a )  possible re-analysis 
 ( b )  analysis for the benefit of members of my immediate family 
 ( c )  research purposes,  subject to the approval of the University of Cape Town Research Ethics 
         Committee, provided that any information from such research will remain confidential. 
  
4. The results of the analysis carried out on this sample of stored biological material will be made known to me,  
via my doctor, in accordance with the relevant protocol,  if and when  available.  
In addition, I authorise that they may be made known to:  (DELETE WHERE NOT APPLICABLE) : 
 other doctors involved in my care 
 the following family members:   ___________________________________________________________ 
 other: _______________________________________________________________________________ 
  
5. I authorise / do not authorise my doctor(s) (DELETE WHERE NOT APPLICABLE) to provide relevant clinical 
details to the Division of Human Genetics, UCT. 
  
6. I have been informed that:  
( a ) there are risks and benefits associated with genetic analysis and storage of biological material and 
these have been explained to me.  
( b ) the analysis procedure is specific to the genetic condition mentioned above and cannot determine 
the complete genetic makeup of an individual. 
( c ) the genetics laboratory is under an obligation to respect medical confidentiality . 
( d ) genetic analysis may not be informative for some families or family members. 
( e ) even under the best conditions, current technology of this type is not perfect and could lead to 
incorrect results. 
( f ) where biological material is used for research purposes, there may be no direct benefit to me. 
  
7. I understand that I may withdraw my consent for any aspect of the above at any time without this affecting my 
future medical care. 
  
8. ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND 
AND MY QUESTIONS ANSWERED BY: 
  



















Page | 117  
 
Appendix D: Sequencing results 
 
Target sequences aligned in BioEdit 
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